



June 11, 1979

## **TRANSCRIPT OF PROCEEDINGS**

---

**IN THE MATTER OF :**

# **Advisory Committee on Health-Related Effects of Herbicides**

---

**Veterans Administration  
Washington, D.C. 20420**

---

1 THE VETERANS ADMINISTRATION

2 \* \* \*

3 ADVISORY COMMITTEE ON HEALTH-RELATED EFFECTS  
4 OF HERBICIDES

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15 The Veterans Administration  
16 Room 119  
17 810 Vermont Avenue, N. W.  
18 Washington, D. C.

19  
20  
21 10:00 a.m.  
22 Monday, June 11, 1979  
23  
24  
25

1      ADVISORY COMMITTEE MEMBERS PRESENT:

2      PAUL A. L. HABER, M.D., Chairman  
3      Assistant Chief Medical Director  
4      for Professional Services  
5      Veterans Administration  
6      Washington, D. C.

7      GERRIT W. H. SCHEPERS, M.D., Vice Chairman  
8      Medical Service  
9      Veterans Administration  
10     Washington, D. C.

11     JAMES R. ALLEN, JR., Ph.D.  
12     Professor of Pathology  
13     The University of Wisconsin  
14     Medical School  
15     Department of Pathology  
16     Madison, Wisconsin

17     IRVING B. BRICK, M.D.  
18     Senior Medical Consultant  
19     National Veterans Affairs  
20     and Rehabilitation Commission  
21     The American Legion  
22     Washington, D. C.

23     J. DAVIDSON ERICKSON, D.D.S., Ph.D.  
24     Center for Disease Control  
25     Birth Defects Branch  
1     Atlanta, Georgia

2     BILL L. STEPHENSON  
3     Environmental Protection Agency  
4     Washington, D. C.

5     PHILIP C. KEARNEY, Ph.D.  
6     Chief, Pesticide Degradation Laboratory  
7     Department of Agriculture  
8     Beltsville, Maryland

9     RICHARD A. LEMEN  
10    Assistant Chief  
11    Industrywide Studies Branch  
12    Robert A. Taft Laboratories  
13    Cincinnati, Ohio

14    ROBERT H. LENHAM  
15    Special Projects Officer  
16    Disabled American Veterans  
17    Washington, D. C.

1 ADVISORY COMMITTEE MEMBERS PRESENT (Cont'd):

2 CAROLYN H. LINGEMAN, M.D. Carcinogenesis Testing Program  
3 National Cancer Institute  
4 National Institutes of Health  
Bethesda, Maryland

5 JOHN A. MOORE, D.V.M. Associate Director for  
6 Research Resources Program  
7 National Institute of Environmental  
8 Health Sciences  
9 Research Triangle Park, North Carolina

10 SHELDON D. MURPHY, Ph.D.  
11 Department of Pharmacology  
12 University of Texas Medical School  
13 Houston, Texas

14 COLONEL J. W. THIESSEN, MC USA  
15 U. S. Army Environmental Hygiene Agency  
16 Aberdeen Proving Ground, Maryland

17 STEERING COMMITTEE MEMBERS PRESENT:

18 RICHARD A. LEVINSON, M.D., Chairman

19 JOHN J. CASTELLOT, SR., M.D.

20 STRATTON APPLEMAN

21 LYNDON E. LEE, M.D.

22 J. C. PECKARSKY

23 FRED CONWAY

24 MARGARET KILDUFF

25 DONELD HOWELL

ALEX KUTNER

PAUL LEGOLVAN, M.D.

## I N D E X

ITEM:	PAGE
Statement by Dr. James C. Crutcher	5
Summary of Steering Committee's Activities by Dr. Richard A. Levinson	21
Statement on Herbicide Research by Dr. Lawrence B. Hobson	30
Report by Dr. Irving B. Brick, The American Legion	37
Report by Dr. John A. Moore, National Institute of Environmental Health Sciences	38
Report by Colonel J. W. Thiessen, U. S. Army Environmental Hygiene Agency	41
Report by Dr. James R. Allen, Jr. University of Wisconsin Medical School	44
Report by Dr. J. David Erickson, Center for Disease Control	49
Report by Dr. Bill L. Stephenson Environmental Protection Agency	51
Report by Dr. Philip C. Kearney Department of Agriculture	53
Report by Mr. Richard A. Lemen Robert A. Taft Laboratories	59
Report by Mr. Robert H. Lenham 'Disabled American Veterans	62
Report by Dr. Carolyn H. Lingeman National Cancer Institute	63
Report by Dr. Sheldon D. Murphy University of Texas Medical School	69
Statement by Mr. Max Cleland, Administrator, Veterans Administration	105
Question and Answer period, and Public Comments	118

P R O C E E D I N G S

DR. HABER: We would like to begin promptly.

Without further ado, I would like to introduce to you our Chief Medical Director, Dr. Crutcher, an outstanding internist, a man who is more concerned I think with clinical practice of medicine in the Veterans Administration than any of his illustrious predecessors.

Dr. Crutcher has taken time from his very busy schedule to address us this morning, and I therefore introduce him to give you an official welcome.

DR. CRUTCHER: Thank you, Paul. The Administrator is receiving his doctorate degree from Emory University in Atlanta, and he is supposed to be making a benedictory appearance this afternoon, but air travel being what it is, he may not make it.

I personally wanted to open up this session because I think the problem of long-term effects of herbicides as it may affect our patients in the Department of Medicine and Surgery is one of significant concern.

I would like to congratulate Dr. Haber and his committee for having gotten such an expert panel, and I would thank those who are on the panel and advisory committee for taking the time from your busy schedules in order to contribute your experience, your talents, and your thoughts regarding this program.

From my perspective, I think the major area of difficulty here will be one of communication. Those of us in the biomedical field often say things and often our

1 patients don't understand what we say, even though we  
2 think it is very simple.

3 Those in the bioscientific field say things that  
4 those of us in the biomedical field hear but do not  
5 understand. Even those who are presenting their scientific  
6 treatise are not perfectly clear to those who are in the group.

7 I know from being on a research and development committee  
8 for many years that sometimes with some of the more  
9 specialized technologies, I couldn't understand the language,  
although I could read the words.

10 Those patients of ours who are neither biomedical  
11 careerists or scientists, but perceive signs and symptoms  
12 as they affect them, and its possible relationship to long-  
13 term effects of herbicides, have their own language and their  
14 own mind set.

15 I think that as a result of this, there is a  
16 possibility of having three groups of people, or perhaps  
17 four--the advocates of the veterans groups, having four  
18 interested groups of people, all well intentioned, all speaking with  
19 somewhat inexperience, ending up that there is a veritable  
20 Tower of Babble regarding this problem; and I think that  
21 the veterans groups and the veterans and the scientists  
22 and the biomedical people should probably be overly  
23 receptive to try and understand what the people are saying.

24 I have absolute confidence in the experience of  
25 this advisory council, but I am speaking as a physician. I  
have confidence in the scientific contributions that many  
of the members of this advisory committee have been

1 making in working on dioxin for many, many years.

2 At the same time, I have a tremendous respect for  
3 patients, and I feel that they have symptoms. They perceive  
4 symptoms that may be related to a specific cause, and  
5 then the ability to transmit or to change their attitude,  
6 or to change our attitude, becomes then a very difficult  
7 problem of who is saying what to whom, and what are we  
8 trying to do.

9 I think finally overall, though, that the  
10 Department of Medicine as part of the VA, is a very personal  
11 agency. We are dealing with people constantly every day.  
12 I dont think we are bureaucratic. Of course, it is up to  
13 us to prove the fact that we are not an insensitive,  
14 bureaucratic agency that is not receptive to what people are  
15 saying, but to put forth the picture that we are a group  
16 of dedicated individuals whose primary goal is to take  
care of those veterans that the law says we ought to take  
care of.

17 I think, Paul, with that as my overview, then  
18 I think this committee can work through these difficult  
19 communication problems, as well as gathering together  
20 some type of logical scientific data and chronology of  
21 whatever effects there may be, at what time, of those  
22 who served in our armed forces.

23 DR. HABER: Thank you very much, Dr. Crutcher.  
We appreciate it.

24 DR. CRUTCHER: It is good to see you all, and  
25 those that are in the audience.

1 DR. HABER: I would like now to move on with the  
2 agenda, and this calls for introductions, and I would  
3 like to ask the Committee and the Steering Committee to  
4 introduce themselves. We are arranged in alphabetical  
order.

5 Would you please give us your name, your  
6 academic or governmental affiliation, and in a few words,  
7 what you do, what is your own particular expertise, whether  
8 you are an epidemiologist or a biochemist or a clinician  
9 or whatever other appropriate designation you need so we  
10 can address you appropriately, and maybe we may begin  
11 with you, Dr. Allen, heading the alphabet.

12 DR. ALLEN: My name is James Allen. I am a  
13 professor of pathology at the University of Wisconsin  
14 Medical School. I have been there for approximately 20  
15 years and during this period, have been  
16 interested in research on the halogenated hydrocarbons  
and the dioxins.

17 DR. BRICK: I am Dr. Irving B. Brick. I am a  
18 professor of medicine and Chief of the Division of  
19 Gastroenterology at Georgetown University School of Medicine,  
20 and also a senior medical consultant to the American Legion.

21 My interest is primarily clinical gastroenterology,  
22 and in particular liver disease. I am going to be  
23 interested myself to learn what these experts are going to  
24 teach me about the effects of these herbicides, particularly  
25 on the liver and other organs in which I am particularly  
interested.

1 Also as a representative of the American  
2 Legion, in handling many claims of veterans before the  
3 Board of Veterans Appeals particularly, the impact of the  
4 findings of this Committee will have great future effect  
5 I think on veterans' claims.

6 All of us in the American Legion are dedicated  
7 to trying to find out the truth over and above the  
8 emotional connotations that have been aroused by the  
9 particular subject that we are going to study.

10 Thank you.

11 DR. ERICKSON: I am David Erickson. I am Deputy  
12 Chief of the Birth Defects Branch at the Center for  
13 Disease Control, Atlanta, Georgia, and I am an epidemiologist  
14 by training and occupation and avocation, and I am primarily  
15 interested in the population dynamics and etiology of birth  
16 defects in humans.

17 DR. KEARNEY: My name is Philip Kearney. I am  
18 the Chief of the Pesticide Degradation Laboratory, U. S.  
19 Department of Agriculture at Beltsville, Maryland.

20 My major interest in this area deals with the  
21 chemistry of the dioxins and their environmental aspects.  
22 I have followed this for about nine years, and I have  
23 visited Italy in '76 and have had a lasting interest in  
24 the environmental treatment and chemistry of the dioxins.

25 DR. HABER: I am Paul Haber, Assistant Chief  
26 Medical Director for Professional Services whose responsibility  
27 it is to help direct patient care programs, and Agent  
28 Orange is something very much in our minds.

1           It is my job to try to get to the bottom of this  
2           for the VA and to advise the Chief Medical Director and the  
3           Administrator, on appropriate steps that need to be taken in order  
4           to solve this problem.

5           DR. SCHEPERS: I am Gerrit Schepers. I work for  
6           the Medical Service in the Veterans Administration. I am  
7           an internist and pathologist by training. I have worked  
8           in the field of toxicology, particularly carcinogenesis,  
9           for the past 25 years, and for the past year, I have been  
10           almost what one might call project officer for our Agent  
Orange problem.

11           Recently we have received all this extra help  
12           so that I need not call myself project officer any more.  
13           Thank you.

14           MR. LEMEN: My name is Richard Lemen, and I am  
15           with the National Institute of Occupational Safety and  
16           Health, and my background is in occupational epidemiology,  
17           and I have done my doctoral training at the University  
of Illinois.

18           I am in charge of the Industrywide Studies  
19           Branch, which is the primary area where long-term chronic  
20           epidemiology is done, and our interest is in the occupational  
21           effects of dioxin and what we might be able to help learn  
22           as far as the environmental effects by looking at occupational  
groups.

23           MR. LENHAM: I am Bob Lenham, the special project  
24           officer for the Disabled American Veterans Organization.  
25           I do not have a scientific background. I am here representing

1 the veteran as a veteran consumer. I am a Vietnam combat  
2 veteran, a hospital corpsman, that was assigned to the  
3 Marine Corps over there, and I, too, share with Dr. Brick  
4 the concerns and the input that we will have from this  
5 Committee and how we shall deal with this input in the  
6 claimants that we represent that come before us, before  
7 the Disabled American Veterans.

8 DR. LINGEMAN: I am Carolyn Lingeman. I am a  
9 pathologist. I work for the National Cancer Institute  
10 and have for the past ten years worked in environmental carcinogen-  
11 esis. We are particularly interested in chemical compounds  
12 which cause cancer. I am also at the present time working at  
13 the Armed Forces Institute of Pathology on a special project  
14 involving attempts to collect pathologic materials from humans  
15 exposed to chemical carcinogens, and the problem is to document  
16 exposure to a toxic chemical and to determine whether or not a  
17 person does indeed have cancer or other disease that could be  
18 attributed to that chemical compound.

19 DR. MOORE: I am Jack Moore, Associate Director  
20 of the National Institute of Environmental Health Sciences,  
21 which is an institute of NIH that is concerned about the  
22 effects of environmental chemicals on the health of man.

23 As a toxicologist, I have been involved for the  
24 last nine or ten years with research trying to understand  
25 what typical benzodioxins as well as other dioxins may do  
on biological systems.

DR. MURPHY: I am Sheldon Murphy, professor of  
toxicology at the University of Texas Health Science Center

1 for approximately the last two years, and 14 years before  
2 that at the Harvard School of Public Health.

3 I have had a long time research interest in  
4 pesticide toxicology, and more recently, association with  
5 the herbicide dioxin problem largely through committees  
6 of the EPA and the National Academy of Sciences.

7 COLONEL THIESSEN: My name is Thiessen. I  
8 represent the Department of Defense, and in every-day life  
9 I am Director of Occupational and Environmental Health at the  
Army Environmental Hygiene Agency.

10 My interest in herbicides is relatively recent.  
11 I was involved as technical adviser to the Defense Logistics  
12 Agency in the disposal of Herbicide Orange.

13 I would like to make the statement that I do  
14 represent a large agency. I do not hold that I know all the  
15 details of the investigations that are going on and the  
discussions that are going on in the Department of Defense.

16 Of course, I will be glad to act as a focal point  
17 and get you all the answers that you need out of the  
18 Department of Defense.

19 DR. HABER: Thank you. As an Advisory Committee,  
20 the most important of our efforts is to secure information,  
21 but I must also inform you that we have a Steering Committee  
in the Veterans Administration which gives us direct advice.

22 Its Chairman is Dr. Richard Levinson, --would you  
23 stand when identified--who is Deputy for Clinical Support  
24 Services; Dr. John Castellot on the Committee who is  
25 Director of our Medical Service, a Vietnam veteran and a

1 veteran of Korea as well--just Vietnam; Ms. Margaret Kilduff  
2 of the administrative staff at the library to give us advice  
3 about the library; Mr. Donald Howell, representing Ms. Dinunzio,  
4 Office of Management Services, and Dr. Paul LeGolvan, Pathology Service;  
5 Dr. Lyndon Lee of the Veterans Administration who is in  
6 charge of one of our research programs; Mr. Tim Conway  
7 representing the General Counsel; and Mr. Charles Peckarsky,  
8 Director of Compensation and Pension Services, Department  
9 of Veterans Benefits.

10 I would like to call to your attention a couple  
11 of people who are going to be helping us--Ms. Williams,  
12 who labored mightily to produce this volume of paper and  
13 who will help us process the material as we go along.

14 I would like to charge the Committee and to give  
15 you some information about what I think our job is and  
16 some information about the way in which we will proceed.

17 I would like to call your attention to the fact  
18 that this Advisory Committee has been duly recognized and  
19 registered, complying with all the rules and regulations  
20 attendant upon such committees, and has been duly published  
21 in "The Federal Register," and future meetings will be  
22 advertised in "The Federal Register" to apprise all  
23 concerned of the occurrence of such meetings.

24 Let me read briefly from the charter of this  
25 Committee. The official designation is Advisory Committee  
on Health-Related Effects of Herbicides, and I will briefly  
read this.

"It has recently been brought to light that

1 enormous quantities of herbicidal chemicals were used  
2 during the Vietnam War, and that there is a possibility  
3 that large numbers of Americans, many of whom now qualify  
4 as veterans, may have encountered these chemicals to an  
5 extent that long-range, significant health problems may have  
6 been initiated.

7 There is considerable controversy in the published  
8 literature and it is probable that much information remains  
9 unpublished.

10 The Veterans Administration has not previously  
11 been required to resolve toxicological issues of such a  
12 complex and highly controversial nature.

13 The Committee will, therefore, assemble and analyze  
14 the information which the Veterans Administration needs in  
15 order to formulate appropriate medical policy and procedures  
16 in the interests of the involved veterans.

17 The Committee will have an entirely fact finding  
18 and advisory role and will not be required to develop policy.  
19 The Committee will adhere to all the provisions of U. S.  
20 Public Law No. 92-463, 5 U.S.C. App. I, Executive Order  
21 12024, and Presidential Circular A-63 of March 27, 1974,  
22 and subsequent applicable revisions.

23 It is anticipated that the Committee may achieve  
24 its objectives within 24 calendar months. However, if an  
25 extension is needed, this will be properly negotiated.

26 The Committee will report to the Chief Medical  
27 Director, Dr. Crutcher, through the Assistant Chief Medical  
28 Director for Professional Services.

1           The Agency responsibility for providing the  
2 necessary support is the Veterans Administration, and  
3 the duties and functions will be quarterly sessions at  
4 the Veterans Administration Central Office in accordance  
5 with an appropriate schedule of dates set at the preceding  
meetings.

6           We will publish a structured agenda. This meeting  
7 will be entirely open today. It is likely that subsequent  
8 meetings will have both an open and a closed portion.

9           I would like to give you a few bits of information  
10 now about procedure. As published in "The Federal Register,"  
11 we will adhere to our agenda. If revisions of that agenda  
12 are necessary, I will call those to the attention of the  
group.

13           We will go through presentations this morning,  
14 beginning with a presentation by Dr. Levinson on the  
15 Steering Committee, a statement of where we are on herbicide  
16 research in the Department of Medicine and Surgery, and we  
17 will then ask for individual reports beginning at eleven  
18 from the members of the Advisory Committee, brief statements  
19 of what your agency or office is doing with respect to  
herbicides, and the determination of their toxicity.

20           This will continue through the afternoon. We  
21 will have an hour and a half break for lunch, and then  
22 there will be the presentation and discussion of written  
23 questions from the VA Steering Committee to the Advisory  
24 Committee. Our Steering Committee has prepared some  
25 questions to which they want the Advisory Committee to relate,

1 and these will be announced so that everybody can hear.

2 Then we will get written questions from the floor.  
3 There will be time for a few statements from people from  
4 the floor, and we will begin that at three o'clock. It  
5 is expected that our Administrator, Mr. Cleland, will join  
6 us sometime later this afternoon, and he may wish to address  
7 those questions himself.

8 I would like to tell you that we encourage any  
9 questions of this group that you may wish to submit. We  
10 would like those questions written, and they should be  
11 submitted to Mrs. Grace Meyer in the back of the room,  
12 and we will then read these at three o'clock. I will read  
13 those, and there may be time, as I say, for a few statements.

14 All of these questions will be answered. All  
15 of those that require answers of a general nature will be  
16 answered, and they will be answered through a mechanism  
17 which I would like to outline, by the members of this  
18 Advisory Committee, and that will be done through  
19 small task forces. If there is a particular area of  
20 expertise in pathology or carcinogenesis we would ask  
21 the official member of the Committee to help us prepare a  
22 paper in answer to that, a position paper.

23 Obviously that can't be done today. It will  
24 take weeks and so on, and my office will endeavor to provide  
25 assistance in framing those answers, or we will prepare the  
paper itself, and then circulate it among the Advisory  
Committee for its answer.

The results of those papers will be available to

1 the public, and we will make it possible so that any  
2 question, any legitimate question which is posed to this  
3 group can receive a duly considered written answer which  
4 will represent the findings of this Advisory Committee.

5 Let me then briefly charge you. You are I hope  
6 impressed, as I am, with the fact that this does represent  
7 a multi-disciplinary group; many kinds of professional,  
8 scientific and technical expertise are represented in  
9 the group.

10 It is also a multi-disciplinary group from the  
11 standpoint of advocacy. There will be various shades of  
12 conviction about the possible connection between herbicides  
13 and long-term pathogenesis. Some of the Advisory Committee  
14 have already distinguished themselves for having contributed  
15 significant works to this body of literature, and I think  
16 that we will hope out of this enlightened discussion to  
17 arrive at the answer.

18 We in the Veterans Administration consider this  
19 a matter of extreme seriousness. The potential link between  
20 exposure to herbicides and long-term pathological effects  
21 is something that has seized the public interest, we think  
22 rightly, and has consumed a prodigious amount of our own  
23 time and expertise.

24 We are grateful to the agencies and organizations  
25 represented around this table for their willingness and  
commitment to help us find these very illusive answers,  
and the answers let me assure you are illusive.

26 We are well aware of the fact that a tremendous

1 amount of literature has been produced. We refer to the  
2 classic study of the National Academy of Sciences in 1974  
3 accomplished with great input from a variety of disciplines  
4 and viewpoints which did not definitely come up with any  
5 evidence of long-term pathological effects in humans upon  
exposure to dioxin and the herbicides.

6 A subsequent study mounted by the United States  
7 Air Force, which was completed last October I believe and  
8 announced by General Dettinger at a hearing before the  
9 House Veterans Affairs Committee looking into this subject  
10 similarly failed to come up with hard evidence of the  
fact that there was a relationship between exposure to  
11 dioxin and long-term pathological effects in humans.

12 Nonetheless, the controversy continues in the  
13 minds of many. The definitive answers are not yet in,  
14 and I think that must, therefore, characterize my charge  
15 to the Advisory Committee. Many are not yet convinced  
16 that such a link between exposure and pathology does or  
17 does not exist, and we have, therefore, to address ourselves  
18 mindful of all the research that has been done heretofore,  
19 but perfectly willing to take a fresh, a new look at the  
evidence already in the files or that may yet be adduced  
20 by appropriate research or introspect.

21 The Veterans Administration has been concerned  
22 with this for the past 15 months, and we continue to be  
23 concerned. Our efforts in this regard can be summarized  
24 under four headings. One is to acquire and exchange  
information. This Advisory Committee is the keystone in

1 that process.

2         Secondly, to disseminate such information to  
3         all of our field installations, hospitals and regional  
4         offices alike.

5         Thirdly, to build and maintain a complete record  
6         and registry of all veterans about whom we know or who  
7         come to us for treatment, or for adjudication of claims  
8         for compensation.

9         Finally, to conduct and offer assistance into  
10         further research into this area. All of our efforts, and  
11         there have been many, come under one or another of those  
12         headings.

13         It has been said that the democratic principles  
14         in which one is presumed innocent until proven guilty should  
15         not apply to chemicals, that is to say, that dioxin should  
16         not be believed to be innocent of pathological effects  
17         until proven guilty, and that certainly is true, but I  
18         would urge all of us to remember that the Veterans Administration  
19         cannot undo what history has done. Try as we will, we  
20         cannot reverse the fact that dioxin is a contaminant and was  
21         sprayed on the fields of Vietnam, and what we now have to  
22         do is not to lament that fact, but to consider whether  
23         or not that spraying did carry with it the possibility of  
24         long-term pathological effects.

25         We know, of course, that dioxin is extremely toxic  
26         in acute situations. There is no question about that,  
27         and we are well minded on that issue, but whether or not  
28         it does produce long-term effects is something that does

1 concern us, and we have to go on about it.

2 We have got to establish that there is a clear  
3 link between pathology and long-term pathologic effects.  
4 We must weigh the evidence. We must consider all the  
5 information. We must conduct a scientific inquiry, although  
6 this is a subject on which emotion swirls about us, and  
7 we are all concerned about the plight of Vietnam veterans,  
8 and if such a link is established, we want clearly to  
9 act on it quickly, prodigiously, and in the appropriate  
fashion.

10 We must not be projected into establishing such  
11 a link until it has been made clearly evident through  
12 scientific inquiry.

13 We want to excite new research if that is  
14 necessary for the Committee. We want to advise the Chief  
15 Medical Director and the Administrator, and indeed the  
16 whole country. I need scarcely tell you that this has  
17 seized the popular imagination, and the public press has  
paid a great deal of attention to this issue.

18 We want to provide answers to the questions.  
19 I would like to say that one thing which I find reassuring  
20 in all this is that at least in the Veterans Administration,  
21 the Department of Medicine and Surgery, we are not waiting  
22 for the answers in order to treat people. That is to say,  
23 if veterans come forward exhibiting pathology or having  
24 symptoms, we would treat them if they are otherwise eligible  
immediately. We do not wait for the deliberations of this  
Committee in order to diagnose and treat. An individual

1 complaining of carcinoma would be treated in the Veterans  
2 Administration whether that was due to prolonged use of  
3 tobacco or exposure to other agents, or exposure to Agent  
4 Orange, so that that decision we don't have to make.

5 Anybody who is now ill, whatever the cause, if  
6 eligible for treatment, would be treated. That does not  
7 minimize the importance of our finding the possibility of  
8 such links, and in a way, gives us only temporary respite  
from the tremendous responsibility thrust upon us.

9 That concludes my charge to the Committee. I  
10 would urge you all to read again the "Federal Register" to  
11 familiarize yourself with the particulars, and I think now  
12 we will move ahead with the summary of the VA Steering  
13 Committee's activity.

14 Tell us where we are in the Steering Committee's  
activities.

15 DR. LEVINSON: Thank you. I will stick to the  
16 time schedule, but during this period, I would like to  
17 introduce, or at least call for brief remarks from members  
18 of the Steering Committee who are most expert in the  
19 particular aspects that I mention.

20 First of all, the Steering Committee was formed  
21 last June at the time when the VA became aware that there  
22 was a major problem concerning the possibility of herbicide  
23 toxicity among Vietnam veterans, and recognized the fact  
24 that our response to this particular situation would have  
25 to be broad based and utilize expertise from throughout  
the agency.

1                   Accordingly, the Committee was constituted  
2 with members from the Department of Medicine and Surgery,  
3 which of course is the health care delivery arm of the  
4 Agency, but also included representatives from the General  
5 Counsel, which is the legal arm, the Department of Veterans  
6 Benefits, which handles the compensation claims, as well  
7 as other matters, from Management Services, which is our  
8 administrative liaison with other agencies, and from our  
9 Research and Development Branch, which is also part of  
DM&S.

10                  The Committee was charged with the task of helping  
11 the Chief Medical Director and the Administrator develop  
12 appropriate policies regarding the diagnosis of herbicide-  
13 related illnesses, the appropriate therapy that is  
14 necessary for any of the illnesses that might be discovered,  
15 and other related matters which might flow from the  
16 demonstration of a distinct connection between herbicides  
and permanent human disease.

17                  This very broad-based charge was then implemented  
18 through a series of separate steps which I will describe  
19 to you briefly. Before I do that, I would like to quickly  
20 list some of the specific charges that the Committee had  
21 and which we hope to be able to fulfill before our tenure  
is terminated.

22                  I mentioned that we provide advice to the DM&S  
23 management, as well as the VA-wide management on policy and  
24 actions related to the herbicides.

25                  Second of all, we are charged with stimulating

1 and coordinating development to new approaches to the  
2 evaluation and treatment of individuals who might suffer  
3 from illnesses arising from exposure to herbicides.

4 Related to that, we had a very specific charge  
5 and that was to develop a program for examination of  
6 veterans who were potentially exposed to herbicides while  
7 in Vietnam, and to evaluate any potential illnesses that  
8 they may demonstrate. I will describe that more later.

9 We attempted also to act as a liaison not only  
10 through our membership, but also through other actions with  
11 the rest of the Agency both in the Central Office and in  
12 the field, and we are available as a resource to conduct  
13 special studies, prepare position papers, and answer  
14 questions posed to the Administrator, the Chief Medical  
15 Director, and others about this general matter, so we are  
16 an interagency clearing, steering and coordinating committee.

17 Just a word about our program for examining  
18 veterans. As has been said, the VA has not dealt  
19 significantly in the past with environmental exposure, and  
20 we have to feel our way slowly, using the best advice that  
21 we could obtain. We will, of course, be asking this  
22 Advisory Committee to give us additional specific directions  
23 in this program, but what we did as a first effort was to  
24 set up an official program for the detection and the  
25 examination of veterans currently in our patient  
population who, A, were in Vietnam during the period when  
the herbicides were used, and B, claim exposure to them.

26 The program consisted of following the

1 identification of these veterans, taking a detailed  
2 medical history which also emphasized the matter of exposure  
3 to the herbicides, and then a physical examination supported  
4 by appropriate special tests which were geared to detect  
5 diseases in the organs that various people had suggested  
6 might be affected on a long-term basis by herbicides.

7 The number of veterans, as you can imagine, in  
8 this category was large. It soon became apparent that we  
9 would have to accumulate this data in some central source  
10 and continue following these people for a number of years  
11 to reach any kind of conclusion about their disease and its  
12 connection to herbicides, and so we proceeded to set up a  
13 registry which we are now in the process of automating  
14 to provide this long-term followup, and to provide a data  
15 base for any long-term studies hopefully of a proper  
16 epidemiological and scientific nature that might arise from  
17 it.

18 We also are attempting with some difficulty to  
19 quantitate the exposure of these individuals to herbicides.  
20 We are doing this by utilizing the spraying tapes which  
21 are available from the Department of Defense that were  
22 used by the NAS in their earlier studies, and information  
23 about the unit histories of the ground troops who saw action  
24 in Vietnam during the period when the herbicides were  
25 used.

26 Our hope is to be able to match these various  
27 sources of data through the computer and to come to some  
28 kind of reasonable conclusion about the presence of a

1 person in Vietnam, and their exposure to herbicides.

2 This has proven to be an incredibly difficult  
3 matter, and we will need your help in attempting to  
4 interpret the sort of data we have. We have many, many  
questions about it.

5 We have also been involved in a coordination or  
6 stimulation sense with a series of research projects,  
7 and Dr. Hobson, a member of our Committee and the Deputy  
8 ACMD for Research and Development, will address future  
9 research in this area separately.

10 I might just mention that Dr. Lyndon Lee, who was  
11 introduced as a member of the Committee, has been coordinating,  
12 directing actually, our study on determining dioxin levels  
13 in fat. This, of course, was suggested as a potential  
14 diagnostic test of great significance.

15 We have done a pilot study. Dr. Lee has been  
16 involved in its direction, and I hope we will have a chance  
17 to hear from him briefly about this matter.

18 Dr. Lee, would you stand and perhaps just say a  
few words?

19 DR. LEE: My background is in general surgery  
20 and pharmacology.

21 In October, Dr. Haber spoke to the Committee,  
22 and Congress, and promised that there would be several and  
23 various studies, one of which was the biopsy of fat for  
24 the assay of dioxin in both exposed people and in controls.

25 In November, he asked me if I could coordinate  
this, and I agreed. We developed a protocol which went

1 through the usual human experimentation approvals, as well  
2 as the research committee approvals in the hospitals,  
3 four of which were in the Chicago area because of several  
4 points.

5 First, we had a good many applications from veterans  
6 in the Chicago area who felt they had been injured by exposure.

7 Second, it was felt that perhaps these people  
8 who came from the more or less urban rather than suburban  
9 or rural area might at least have had less exposure as  
10 civilians than others from the farm areas.

11 And lastly the men were interested and could  
12 be persuaded to follow the program.

13 We also added one further hospital in Lincoln,  
14 Nebraska, because that was where the chemist who was to do  
15 our assays was centered, at the university, and we needed  
16 liaison, so we added one man there.

17 We have approached the National Academy of  
18 Sciences National Research Council through their followup  
19 agency for statistical participation, and that is being  
20 carried out. The protocol has been approved. We now have  
21 taken biopsies from 16 individuals; 14 of these have been  
22 exposed anywhere from 13 days to 6,600 hours of documented  
23 exposure, and these biopsy reports are not yet available.

24 There have been two controls which have had  
25 biopsies, and there are four more individuals to be  
biopsied this week, two additional who have not been  
scheduled, and that is the report at the present time.

1           Obviously we have not broken the code. These  
2 various materials have been sent to the biochemist coded  
3 so that he does not know what types of exposure, if any, the  
4 individuals have had, and will be prepared I think to give  
5 a more full report on this within probably another month.

6           DR. LEVINSON: Thank you. May I ask Dr. LeGolvan  
7 to just say a word to you? He is the Deputy Director of  
8 our Pathology Services--to say a word or two about the  
9 program with the Armed Forces Institute of Pathology with  
10 regard to the storage of biopsy and autopsy tissues from  
11 veterans exposed to herbicides who come through our hospital.

12           DR. LeGOLVAN: I am a pathologist in the Pathology  
13 Service with Dr. Williams. Our negotiations with the AFIP  
14 resulted in the establishment of a registry of tissue  
15 pathology for the cases that might appear at the AFIP,  
16 and listing possible exposure to herbicides.

17           In this registry, any tissues that are sent to  
18 the AFIP will be so coded for future study. These cases  
19 all are such that all hospitals have been notified that  
20 any cases that appear for routine surgery of any type or  
21 for any other studies in which tissues are obtained will  
22 be sent to the AFIP for this registry.

23           Thank you.

24           DR. LEVINSON: Thank you. Another function of  
25 our Committee is to attempt to increase the understanding  
of particularly our professional staffs in our hospitals  
and clinics about the matter of herbicides and other  
environmental toxins, and to make them more aware of the best

1 ways in which to examine veterans who claim or who should  
2 perhaps be claiming possible illnesses related to these  
3 agents.

4 We have done this in a fairly formal way through  
5 hot lines and circulars and other publications. We are  
6 planning some major educational activities in the near  
7 future, again hopefully with the help of this Committee,  
8 the Committee's expertise to offer more detailed educational  
9 information about the appropriate matters.

10 We have also attempted to answer appropriately  
11 the many requests for information from the press and radio  
12 and television. In that, we have the great help of Mr. Stratton  
13 Appleman, the man sitting in the back, who is a member of  
14 our Steering Committee, and hopefully, we are increasing  
15 the amount of specific and appropriate information of the  
16 public at large through most of these news releases.

17 Another matter that we are concerned with is  
18 compensation. Compensation for Agent Orange related  
19 matters is the province of the Department of Veterans  
20 Benefits. One of our members, Mr. Peckarsky, is from the  
21 Department of Veterans Benefits, and I will ask him to just  
22 say a few words to you about our present status in that  
23 matter.

24 MR. PECKARSKY: For me, this type of session is an  
25 extreme learning process. We are fortunate in that the  
law, with regard to veterans benefits does not require the  
establishment of a causal relationship between subsequently  
experienced disability and any incidence of service.

1                   In that regard, any disability that is incurred  
2                   or aggravated at a coincident point of time with military  
3                   service receives the status of service connection.

4                   Nonetheless, it is important in the lapse of  
5                   time that has taken place since the exposures in service  
6                   that we learn as much as we can concerning the effects in  
7                   the out years of exposures to dioxin. This we expect to  
8                   get from our participation in this Committee's work.

9                   DR. LEVINSON: Thank you. Just in conclusion,  
10                  I would like to point out that the Steering Committee will  
11                  continue to carry out its various missions and perhaps  
12                  add additional ones as they appear appropriate.

13                  In doing so, of course, we need all of the expert  
14                  scientific and medical information that we can obtain on  
15                  this matter towards that end. Our group compiled a series  
16                  of questions which you will hear about this afternoon, in  
17                  areas that we feel answers are very important, and we stand  
18                  ready to assist you in any way in better carrying out your  
19                  advisory function.

20                  Thank you very much for your time.

21                  DR. HABER: Thank you, Dr. Levinson. We really  
22                  would be quite powerless to implement the advice of the  
23                  Advisory Committee were it not for the existence of the  
24                  Steering Committee.

25                  We look forward to their continued input and the  
26                  ability to translate some of this advice into specific  
27                  rules and regulations so we in the Veterans Administration  
28                  can                   implement the advice of this Advisory Committee.

1                   On our agenda next is a discussion of herbicide  
2 research. I would like to introduce Dr. Lawrence Hobson.  
3 Dr. Lyndon Lee described the fat biopsy study. I would  
4 indicate to you that the basic idea for the protocol  
5 emanated from Dr. Hobson, and he might wish to tell you a  
6 little bit about what he had in mind on that, as well as  
7 what the Office of the Assistant Chief Medical Director  
8 for Research and Development will be doing to help us  
9 in the VA to research into this area.

10                  DR. HOBSON: In a sense, I am bringing the coals  
11 to Newcastle by talking to this group since many of you  
12 are much more expert in this particular area than I am.  
13 I will just very briefly sketch why the fat biopsy program  
14 is undertaken.

15                  The claim was made in a television interview that  
16 fat would retain dioxin for decades in an inactive form,  
17 and that anything that mobilized the fat, for example, a  
18 reduction program, during or at the end of those years,  
19 would release dioxin in the circulation and produce a  
20 problem of dioxin intoxication.

21                  This, of course, requires that dioxin be stored in  
22 fat, and the most direct way to determine that is by  
23 a sensitive assay method to detect the dioxin.

24                  We sought the advice of EPA as to what assay  
25 technique was best and who was the best one to apply it  
and were given the name of a man who had shown the best  
results in the sense of consistency, sensitivity, in this  
assay, and we, therefore, contracted with him to carry out

1 the determinations in part because he had the best test  
2 and because he is not in the VA or in the federal  
3 government and therefore would not be biased in his result  
4 and we further stipulated that the samples be submitted  
5 to him blind so he has no knowledge of what exposure the  
6 individual may have.

7 As Dr. Lee has said, there is a variety of  
8 exposures here so that when the assays are completed, we  
9 will be able to say whether in fact it is possible to  
10 detect this material in fat, and if so, to what level,  
11 and if it is detectable, whether there is any difference in  
12 the amount of dioxin determined in the fat of individuals  
13 who had military exposure, and the balance of us who have  
14 simply been in the civilian population or were in the military  
15 but not in the areas in which it was being used.

16 This is not an attempt to arrive at a definitive  
17 epidemiological study at this stage of the game: until we  
18 find that this most sensitive method can detect dioxin  
19 it would be rather foolish and fruitless to have a large  
20 number of people examined.

21 These are biopsy specimens and they require an  
22 operation so that we are not anxious to subject individuals  
23 to that to no end at all.

24 The other research that has been proposed to us  
25 in large part has been accomplished already. Dioxin itself  
and the herbicides have been the subject of extensive  
research, as all of you know I'm sure. The one area that  
has been suggested might be unique for the VA is

1 epidemiological studies of individuals who have been  
2 exposed.

3 The difficulties here, as I am sure all of you  
4 appreciate, are in the documentation of the precise level  
5 of exposure because the mere presence in Vietnam of an  
6 individual does not mean he was anywhere near the sprayed  
7 area, and presence in a sprayed area does not necessarily  
8 mean that he was there at the time when dioxin was present,  
9 so that we are really in a very difficult position in  
10 attempting to do definitive epidemiological studies of this  
material under those circumstances.

11 We feel that much better studies can be conducted  
12 in the sense of knowing at least the time, approximately  
13 the amount of exposure in industrial accidents or industrial  
14 exposures such as those that have occurred in the past,  
but not within the veteran group.

15 The one symptom or sign that seems to be generally  
16 accepted as evidence of exposure to dioxin is the appearance  
17 of chloracne, which is a skin condition.

18 As you know, the difficulty with using this as a  
19 criterion is that the military in most instances under  
20 field conditions did not record chloracne as a significant  
21 finding. It didn't endanger the individual's health. It  
22 was often confused with other skin conditions which were  
23 equally benign if treated, and there was not much made of  
24 it so that the record of individuals who may have had  
25 chloracne in Vietnam is really very scanty and probably non-existent. At least we have been unable to recover them.

1                   Lacking that, the level of exposure, the amount  
2 of material to which the individual was exposed, let alone  
3 absorbed, is a matter of conjecture and we are not going  
4 around and exposing people to highly toxic material in  
5 an attempt to find out what is going to happen to them, so  
6 that we are quite handicapped.

7                   I would raise one other point here which I am  
8 afraid is a very negative one and rather unpopular with  
9 known scientists, and that is that scientists are not all-  
10 powerful. We can't do everything. One of the things  
11 we can't do is to prove a negative. We can't say that  
12 something did not or cannot occur, and yet we are constantly  
13 being asked a question which is a very reasonable one in  
14 lay terms, namely, prove that nothing did happen or that  
15 nothing can happen, that you can't get cancer from this  
16 or you won't get sick from that.

17                  This is, as I said, scientifically impossible  
18 to do. Let me demonstrate that very, very briefly. If  
19 you examine 100 people, and none of them had an effect, for  
20 whatever reason, you can say well, there was no effect,  
21 but somebody can say, but the 101st man may have got it, so  
22 you do 1,000, and you still don't find any effect, and  
23 they say well, but the 1001 may have got it, and you can  
24 continue this kind of endless chain in perpetuity and never  
25 be able to say that it cannot happen.

26                  The best you can hope to do is to say that there  
27 is less than a certain chance that it would happen, not that  
28 it cannot.

1                   The result of whatever kind of scientific studies  
2 that are carried out are going to be couched in terms that  
3 are going to disappoint some people because it will not  
4 say flatly that a certain thing did not or could not  
5 appear.

6                   I think you have to keep this in mind when you  
7 look at research plans and research that has been conducted  
8 and not expect that you are going to get a flat answer that  
9 it cannot or won't happen.

10                  We are at the present time dependent on an  
11 epidemiological study on the identification of individuals  
12 who were presumably, and with a strong level of presumption,  
13 exposed to dioxin, where there are certain groups where we  
14 know that was true; people who handled the defoliants and  
15 who were not particularly careful about it undoubtedly  
16 got exposed to the defoliant, and presumably to dioxin.

17                  People who went into areas where the spraying  
18 had been done were only presumptively exposed, and it will  
19 probably wind up that that is the best epidemiological  
20 group we can find, but it is rather unsatisfactory from  
21 the scientific point of view, and it certainly will not,  
22 as no other study would do, establish the negative if we  
23 find that there is no ill effect in whatever group it is  
24 that we examine.

25                  DR. HABER: Thank you very much. Dr. Hobson  
26 has been the recipient of a memorandum from me asking that  
27 our Research and Development Service consider the likelihood  
28 of other kinds of research, and we will be getting an answer

1 from him and their own advisory committee as to the feasibility,  
2 likelihood, and necessity of the Veterans Administration  
3 initiating additional studies in certain specific areas  
4 that were suggested to him.

5 We look forward to his continued operation and  
6 cooperation in this activity.

7 I would like to call attention to the presence  
8 of Dr. Stephenson representing Dr. Griffith from the EPA,  
9 and we welcome you, Dr. Stephenson.

10 DR. STEPHENSON: Thank you.

11 DR. MOORE: Dr. Haber, may we interrupt for  
12 questions?

13 DR. HABER: I think that what I would like to  
14 suggest is that if you have procedural questions, any time  
15 is appropriate. If they are substantive questions, I  
16 would like to delay that until either your presentation,  
17 which we are about to ask for now, or until the time for  
18 the questions.

19 DR. MOORE: It is a question that is prompted  
20 by the presentation. I will pose the question and if you  
21 want to hold it, fine.

22 DR. HABER: Yes.

23 DR. MOORE: With regard to the biopsy specimens  
24 that have been taken and that have been coded to be analyzed,  
25 is it possible to find out what levels of detection they  
are going to attempt to look for, PCD or put in positive  
controls of that type? Is that type of information available,  
or can it be made available?

1 DR. HABER: I would defer that to Dr. Lee.

2 DR. LEE: The level at which they can determine  
3 the presence of dioxin is one part in a trillion. They  
4 will report in units, giving us an idea, if there are any  
5 dioxin units present, how many these may be against controls  
6 which obviously may themselves show dioxin levels, but we  
are not certain about that.

7 DR. HABER: Okay. I think this question needs to  
8 be dealt with more fully, and we will this afternoon. I  
9 quite agree. I think at this juncture now we would like  
10 to go around the table and begin the process of reporting.

11 We will not be able to observe the alphabetical  
12 regularity with which we asked you to be seated because some  
13 of you have to leave earlier.

14 I would like to ask you to take 10 minutes or  
15 minutes if that is required for the purpose of giving  
16 us a brief on where your particular agency or office is  
17 at this point, and I think also what questions you would  
18 like to see this group address as well, and in brief  
19 to let us know where you come from and to share with us  
a summary of your experience.

20 As I indicated, since some of you will have to  
21 leave earlier, I would ask your forbearance in departing  
22 from the otherwise assigned alphabetical listing, and with  
23 that, I would like to ask Dr. Brick representing the  
American Legion, and himself, to begin.

24 Dr. Brick, would you tell us what you are doing  
25 and what you would like to see solved in this area?

1 DR. BRICK: I am interested in the general  
2 problem of the long-term effects of dioxin as outlined in  
3 the charge to the Committee.

4 Representing the American Legion, we are  
5 interested in that particularly from the point of view of  
6 the compensation angle which is represented here by  
7 Mr. Peckarsky, and as he pointed out, he is interested, too,  
8 to know whether these problems are real, imagined, what  
the extent of the problems is, and that type of thing.

9 From a professional point of view, I am  
10 particularly interested in the effect of dioxin and its  
11 effects on the liver and whether or not any of the liver  
12 diseases that we commonly encounter have anything to do  
13 with the exposure that may have been obtained in Vietnam.

14 I am not as familiar with the literature as  
15 some of the experts here. I don't pretend to be, and have  
16 a question about whether or not the National Academy of  
17 Science's report, and the Air Force report might be made  
18 available to some of us in the Committee who have not seen  
these reports. I think that might be helpful.

19 Also a question, Dr. Haber--minutes are being  
20 taken of this meeting, and will they be available to the  
members of this Committee?

21 DR. HABER: Absolutely.

22 DR. BRICK: Not all of us are going to be present  
23 at all of the meetings, and/or all of the meetings in toto,  
24 and if such materials are made timely available to us, I  
25 am sure that many of us will, in our own leisure, study these

1 and have questions and possibly some suggestions.

2 That is the end of my presentation.

3 DR. HABER: Okay. Dr. Moore, I understand you  
4 may have to leave. Would you, therefore, please address us  
5 and tell us what you have been doing and what questions  
6 you would like to see answered and so on?

7 DR. MOORE: As I mentioned in introducing myself,  
8 we have done work with tetrachlorodibenzodioxin, TCDD,  
9 and other dioxins for nine or ten years.

10 Our original work was trying to establish whether  
11 or not the benzodioxins can produce teratogenesis or other  
12 effects, or birth defects.

13 Since that time, we have tried to look into the  
14 types of effects that the benzodioxins may cause. We  
15 have not restricted ourselves to TCDD. Indeed, TCDD is but  
16 one member of a family of dioxins, others of which can  
17 cause toxicity.

18 I would like to point out to the Committee's  
19 attention if they are not aware of it, the evidence that  
20 is accruing over the last few years is clearly showing  
21 that a variety of chemicals that are called halogenated  
22 hydrocarbons may have the same target site for whatever  
23 effect they do produce, and so therefore, if one is looking  
24 for illness as a consequence of dioxin exposure, the  
25 expression of that illness may be a total insult, if you  
will, from TCDD, other dioxins, chlorinated dibenzofurans,  
possibly azoxybenzenes, hydrochlorinated biphenyls. In  
other words, you can't consider TCDD exposure in a vacuum

1 is basically what I am saying.  
2

3 I would like to point out two publications that  
4 have not been mentioned heretofore, and I think the  
5 Committee should be aware of their existence and may want  
6 to look at them.

7 One is a publication that came out of Sweden  
8 which is a culmination of a conference which was hosted  
9 by the Royal Swedish Academy of Sciences two years ago  
10 on chlorinated acids and their dioxins.

11 Aside from wanting to look at the recommendations  
12 that the various groups may have had in there, it is a  
13 fairly up-to-date background reference to what is in the  
14 literature and what may or may not be of interest.

15 DR. HABER: We are in debt to you for bringing  
16 that to our attention. I would hope that others of you if  
17 you know of significant publications would bring them to  
18 our attention. We will try to make them available if we  
19 can.

20 DR. MOORE: The second one is much briefer in  
21 size, and it is a technical report of a meeting that  
22 was held in January of 1978 in Lyon, France under the  
23 sponsorship of the National Institute of Environmental  
24 Health Sciences and the International Agency on Research  
25 in Cancer, which is part of the WHO.  
:

The one-week meeting was to in essence see if one  
could come to grips with the long-term hazards of poly-  
chlorinated dibenzodioxins and polychlorinated dibenzofurans.  
There are some recommendations in this, but aside from

1 the recommendations, I would again urge the Committee  
2 members to look at this as well because it does give a  
3 fairly good summary of the previous occupational exposures,  
4 the date they occurred, the numbers of populations that  
5 were involved in the exposures, and what is the current  
6 monitoring aspects of them, and I also tend to feel that  
7 if one is going to get insight fairly soon as to the chronic  
8 effects of exposure to dioxins or herbicides, it is going  
9 to be from some of these worker populations where their  
exposures are now approaching 20 to 30 years.

10 Unfortunately, the numbers are very small.

11 DR. HABER: Dr. Moore, is it fair to ask is your  
12 office engaged in any of those long-term follow-up studies  
13 now underway, the group at Nitro, or have you any input  
into that?

14 DR. MOORE: Indirectly. The Nitro, West Virginia  
15 group that was followed up, the clinical examination  
16 I believe, at least in part was done by the Mount Sinai  
17 School of Medicine, which is funded through our grant program.

18 DR. HABER: You will be getting those answers,  
will you not?

19 DR. MOORE: Yes. I believe NIEHS has a formal  
20 affiliation.

21 DR. HABER: That is one of the things I would  
22 like to do, to try to pinpoint who would be likely to  
23 find out.

24 Thank you very much, and we are indebted to you  
25 for calling those publications to our attention.

1 I think next, Dr. Thiessen, if you would be  
2 good enough to address us and we would like particularly  
3 if you can help us with that information, I understand  
4 your earlier statement about the complexity of the  
5 Department of Defense's research assistance on this, but if  
6 you can give us any information about the Air Force projected  
7 study, that would be most helpful.

8 COL. THIESSEN: Let me again reiterate that I  
9 am not familiar with the details of the Air Force study.  
10 The Air Force has been so kind as to give me  
11 a general statement that I would like to read into the  
12 record.

13 Let me make it clear that the Department of Defense  
14 intends to and has in some cases involved institutes such  
15 as the Armed Forces Institute of Pathology that has been  
16 mentioned before. The Armed Forces Epidemiology Board  
17 will discuss the study protocol that is being developed by  
18 the Air Force.

19 The study protocol will be brought before this  
20 Committee for at least advice, if not approval, and all  
21 these actions should take place pretty shortly, if they  
22 haven't taken place already.

23 Now the Air Force will conduct a study of the  
24 health of Ranch Hand personnel involved in the aerial spraying  
25 of Herbicide Orange in Vietnam. Operation Ranch Hand was  
a code name attached to the Air Force air crews between  
1962 and 1971, when the operation ceased.

26 These personnel would have been the most likely

1 to have had significant exposure.

2 The purpose of the study is to determine if any  
3 causal relationship can be established between exposure  
4 to these herbicides, and changes in the long-term health  
5 status of the individuals involved.

6 The study will involve both veterans and active  
7 duty personnel; former Ranch Hand personnel exposed to  
8 Herbicide Orange, approximately 1200, will be carefully  
9 matched to a control group not exposed. Detailed telephone  
10 health surveys will be given all members of the study  
11 beginning in early October 1979. Comprehensive physical  
12 examinations will be given to a selected number of both  
13 exposed and non-exposed individuals. Health surveys  
14 and scheduled physical examinations of selected individuals  
15 will be conducted for a minimum of six years to see if any  
16 long-term health problems emerge.

17 The entire study will be completely reviewed by  
18 both government and civilian scientific personnel. This is to  
19 preclude any bias, and to ensure the scientific validity  
20 of this complex project.

21 The study details, as I said, will be presented  
22 to this Committee during this review cycle.

23 That concludes my statement.

24 DR. HABER: I would like to suggest to the  
25 Committee that in a prior meeting that I had with General  
Dettinger on the study, I asked of him permission for this  
Committee, this Advisory Committee, to get the protocol,  
which was granted, so when that protocol is delivered to us

1 we will circulate it among the Committee. I think this  
2 is really only in the interest of scientific exchange,  
3 though some of you may have some suggestions about this  
4 and possible suggestions of revision of the protocol which  
5 I think would have to be done fairly soon if we were  
6 going to do anything about it, but I must tell you the  
7 Department of Defense and the Air Force have their own  
8 scientific review process, and it strikes me that they are  
well along in this process.

9 Isn't that right?

10 COL. THIESSEN: Yes.

11 DR. HABER: What are the bodies that would review  
this?

12 COL. THIESSEN: The Armed Forces Epidemiology  
13 Board for the Armed Forces in general, and the Scientific  
14 Advisory Board of the United States Air Force for the Air  
15 Force.

16 DR. HABER: Then it will have been subjected to at  
17 least two prior in-depth reviews, but I asked  
18 for the opportunity for our group to see it and review it,  
19 and I think we should avail ourselves of that. In  
20 some subsequent meeting, you may wish to go on record  
21 individually or collectively as, hopefully, approving the  
study.

22 COL. THIESSEN: Let me also state for the record,  
23 sir, that the Armed Forces Epidemiology Board does not  
24 consist of Army representatives, but of national experts.

25 DR. HABER: I am well aware of that, and

1 General Dettinger was quite informative on that subject.

2 Okay. I think with those presentations, we  
3 ought to now proceed to ask the other members of the  
4 group in alphabetical order. Dr. Allen, I guess that  
5 puts you up first. Will you please tell us where you are  
6 in your research and what your plans are and what you  
7 would like for us to help you with if we can?

8 DR. ALLEN: I would like to say that I am an  
9 experimentalist. I have done no research at all on human  
populations that have been exposed to dioxins.

10 I have done no research on Agent Orange per se.  
11 My research has been limited primarily to the  
12 tetrachlorinated dibenzodioxins and their effects on non-  
13 human primates, the Rhesus monkey and on rodent populations,  
14 primarily the laboratory rat.

15 We have found that a relatively low level of  
16 exposure to the dioxins, namely, TCDD, is extremely toxic.  
17 In some of our initial studies, we found that levels, when  
18 consumed at 500 parts per trillion in the diet for a period  
19 of nine months, produced mortality in over 50 percent of  
the experimental animals.

20 Within a period of three months, the animals began  
21 to lose their hair, had swollen eyelids, dry, scaly skin,  
22 and indications of hematological abnormalities.

23 At these levels of exposure  
24 they had consumed in the neighborhood of 1 microgram per  
kilogram of body weight.

25 By the sixth month of exposure, and after having

1 consumed in the neighborhood of 2 micrograms per kilogram  
2 of body weight, the animals developed what we would consider  
3 a severe pancytopenia, decrease in circulating white cells  
4 and red blood cells, and a marked decrease in blood platelets.

5 At this time, we attempted to breed the eight  
6 experimental animals; three of the eight became pregnant.  
7 Two aborted early in gestation, which is an indication or  
8 suggestion of difficulties that we have observed in other  
9 studies, in the halogenated hydrocarbons and its effect  
upon the reproductive capability.

10 At seven months of exposure, we lost our first  
11 experimental animal primarily due to excessive bleeding all  
12 over the body. By the ninth month, we had lost our second  
13 animal due to widespread hemorrhage, and by the 12th  
14 month, we took the animals off the experimental diet.

15 At nine months, they had consumed in the neighborhood  
16 of between 2 and a half to 3 micrograms per kilogram of  
17 body weight.

18 During the succeeding three months up to the 12th  
19 month, we had lost three additional animals, making a total  
20 of five of the eight experimental animals that died from  
21 dioxin intoxication.

22 Some of the more pertinent lesions that we  
23 found in these experimental animals, in addition to  
24 the loss of hair, loss of eyelashes, swollen eyelids, dry,  
25 scaly skin, keratinized hair follicles, there was a marked  
thickening of the gastric mucosa, ulceration. There was  
marked dilatation of the gall bladder, and hypertrophy

and dysplasia of the epithelium of the gall bladder, as well as the common, cystic and hepatic ducts and the bile ducts within the hepatic tissue.

There were hypoplasia and metaplasia and dysplasia in the sebaceous glands, the salivary glands, metaplasia and hyperplasia of the transitional epithelium of the urinary bladder, and also metaplasia and hyperplasia of the lining of the mucosa of the stomach.

In subsequent studies, we have reduced the level of dioxin in our experimental diets to 50 parts per trillion. These animals now have been on this diet for over two years. After six months of exposure and after having consumed in the neighborhood of about 3 tenths of a microgram per kilogram of body weight, we attempted to breed the experimental animals.

Of the eight experimental animals, six became pregnant. Four aborted early in gestation, and two were able to carry their infants to term, thus further clarifying or substantiating the observation of the effect of dioxin upon the reproductive capability of non-human primates.

The animals have been on the diet for approximately two years. They have consumed in the neighborhood of one microgram per kilogram of body weight, and are beginning to show the same signs and lesions that developed in the 500 parts per trillion animal of three months, both groups having consumed in the neighborhood of one microgram per kilogram of body weight.

Thus in these studies it would appear that there

1 are very distinct changes that occur. When the  
2 levels of exposure to the dioxins are higher some changes occur much  
3 more rapidly than when the level of exposure is quite low.

4 It would appear that the same effects develop  
5 in the experimental animals, regardless of the time that  
6 is required, whether it be three months at 500 parts per  
7 trillion, or at 50 parts per trillion over a two year  
period.

8 This pretty well brings you up to date as to what  
9 are the effects that we have observed in our non-human  
10 primates. We now have studies that are on going where  
11 we are feeding animals 25 parts per trillion of  
12 tetrachlorodibenzodioxins. They are being bred at the  
13 present time to determine if these levels will have effects  
14 upon the reproductive capability, and the general body  
health of these experimental animals.

15 I would like to mention just briefly our  
16 preliminary work with the possible carcinogenic effects  
17 of the tetrachlorodibenzodioxin. We did a pilot study  
18 approximately three years ago where we had fed rats levels  
19 of dioxin ranging between 5 parts per billion and 5 parts  
20 per trillion.

21 Those animals that died during the course of the  
22 experiment had approximately a 37 percent overall incidence of tumors.  
23 Those that were sacrificed after two years on the diet had  
24 approximately a 36 percent incidence, overall incidence of  
tumors.

25 The tumors that were observed were quite variable,

1 involving the liver and the lung. Those two organs were the  
2 more severely affected.

3 These observations have been substantiated at a  
4 somewhat higher level by the Dow Chemical Company scientists  
5 and certainly there are indications from the Illinois  
6 Institute of Technology that there are carcinogenic  
7 effects of tetrachlorodibenzodioxin.

8 Recent reports at the American Association for Cancer  
9 Research meetings in New Orleans strongly indicated

10 the promotional activities  
11 of the tetrachlorodibenzodioxins on cancer. Thus it would  
12 appear that we are working with an extremely toxic compound  
13 that has widespread effect on experimental animals.

14 DR. HABER: Thank you. I am sure there will be  
15 questions about it this afternoon. We would like to ask  
16 you to elaborate.

17 DR. ALLEN: In our  
18 evaluations of populations that have been exposed to  
19 dioxin I do not think that we can eliminate those that  
20 have been chronically exposed or have low-level exposure.

21 In work done at the National Institute of Environmental  
22 Health Sciences, they were able to show that some of the  
23 same signs and lesions were produced at levels of 70 micrograms per  
24 kilogram of body weight that we observed in the neighborhood at levels  
25 of 2 to 3 micrograms per kilogram of body weight over an  
extended period of time.

26 There may be heavy exposure which produces the  
27 effect, but this does not eliminate the possibility of low-

1 level exposure that may occur over an extended period of  
2 time that may produce this same effect, and these are what  
3 I consider extremely pertinent points, and I have received  
4 unofficial reports since, that in some of the peripheral  
5 areas that are involved, some of the people are beginning  
6 to show ill effects that were not observed in the more  
acutely exposed areas.

7 DR. HABER: Thank you, Dr. Allen. We certainly  
8 appreciate your statement.

9 I would like to move on. Dr. Erickson, can you  
10 please tell us what your laboratory has been doing and  
11 can you shed any light on this problem for us?

12 DR. ERICKSON: As I said when we introduced  
13 ourselves, I come from a group that is interested in the  
14 occurrence of birth defects in humans.

15 We have no experience whatsoever in dealing with  
16 this problem from the angle of herbicides. We got into  
17 the business that we are in, I think, because of another  
18 environmental exposure---that was thalidomide. There was a  
19 good deal of interest generated in the early '60's by the  
20 disaster which happened in Europe and in the other parts  
21 of the world, the epidemic of limb reduction deformities  
22 that were a result of maternal ingestion of thalidomide.

23 This epidemic wasn't discovered until a few  
24 years after it began, and the people got the idea if there  
25 were monitoring programs in place that the epidemic of this  
thalidomide syndrome babies would have been discovered  
earlier, and so at the Center for Disease Control, we

1 monitor the incidence of birth defects in human populations.

2 This monitoring of the trends is useful for  
3 two purposes I would think. One is to detect an epidemic  
4 of birth defects which might be due to the introduction  
5 into the environment of a new teratogen or due to the  
6 change in the prevalence of an old teratogen.

7 The monitoring programs also provide a somewhat  
8 unique data source for the mounting of special studies  
9 into the etiology of human birth defects.

10 We have two main programs in our branch. One  
11 is called the Birth Defects Monitoring Program, and it is  
12 a quasi-national program covering about a third of the  
13 births in the United States each year.

14 The other program is in metropolitan Atlanta  
15 and is a higher quality system, a more intensive type  
16 of ascertainment, but monitors only about 25,000 births per  
17 year.

18 I would just like to make a couple of comments  
19 about the epidemiology of birth defects in humans. People  
20 talk about birth defects, but there are really probably  
21 several hundred different kinds of birth defects, and each  
22 of these is probably a unique disease or a somewhat unique  
23 disease; at least from what we know about animals, and  
24 their reaction to teratogens, and the few known human  
teratogens, we have the idea that each teratogen or defect-  
causing substance produces a fairly unique type of mal-  
formation or syndrome of malformations.

25 Also each different type of defect is individually

rare. The most common ones occur at a rate of about one per thousand births, and so studies to discover causes of these things are very difficult and very time consuming and very expensive.

The last point I would like to make is that so far as we know, birth defects have been around for a long time, and with a few notable exceptions, the rates have remained fairly stable, and they are relatively stable around different areas of the world as well.

The notable exceptions I would like to point out here in the United States are three. First, we think there is pretty good evidence that the defects of the central nervous system are decreasing.

Over the past decade, we believe they have decreased at an annual rate of about 5 percent per year, and we believe that this decrease is real. We have no explanation for it, however.

Two, heart defects, ventricular septal defect and patent ductus arteriosus, have been on the increase during the last decade. They have been increasing at the rate of about 10 percent per year.

We again have no explanation for this increase. We are unsure whether it is real or not, or whether it is simply a matter of increased awareness on the part of pediatricians who are caring for sick newborn babies who are surviving longer now, and they have immature hearts when they are born.

The last defect which seems to be on the rise is

1 renal agenesis, and this may be a real increase, or it may  
2 be due to increased use of diagnostic technologies which  
3 weren't used in previous decades.

4 I think that's all I have to say, Dr. Haber.

5 DR. HABER: We welcome your interest in this field.  
6 You have much to contribute.

7 May we go on? Dr. Stephenson, do you want to  
8 briefly tell us what it is you do for a living because  
9 we went around the table and introduced the group so we  
get some idea of what special interest you have.

10 DR. STEPHENSON: Thank you, Dr. Haber. My  
11 background is industrial hygiene in particular. I am  
12 standing in this morning for Dr. Griffith, who is an  
13 epidemiologist, and I didn't know that we were going to be  
14 asked to give a review, but I will tell you rather briefly  
15 what EPA has done and somewhat what they are planning to  
do.

16 The EPA has done a descriptive epidemiologic  
17 study in Oregon where they were looking at spontaneous  
18 abortions, and this was not a cause and effect type study,  
19 but merely descriptive, and I would like to emphasize that.

20 Through this study, the Agency saw its way clear  
21 to issue an emergency suspension of 2, 4, 5-T, which in  
22 essence gives the Agency an additional year to weigh  
23 scientific evidence to the effects of 2, 4, 5-T, and this  
24 fall, hearings for the cancellation of 2, 4, 5-T registration  
25 will begin, and at that time, more scientific evidence will  
be submitted for cause and effect type look by scientists

1 as to the results of 2, 4, 5-T exposure to the general  
2 population.

3 I believe, Dr. Haber, since we will be in  
4 litigation, that is about all that I have to say now.  
5 So far as the design and particulars of the study done in  
6 Alsea, Oregon, Dr. Griffith is certainly familiar with  
7 those, being the primary epidemiologist in that study,  
8 and certainly will be available to this most distinguished  
9 group to lend his support in additional meetings, so with  
that, I would like to close.

10 DR. BRICK: I would just like to ask a question.  
11 You said new studies were being done. Are they of the  
12 same sort as were done in Alsea.

13 DR. STEPHENSON: Well, what we would like to do  
14 are some follow-on studies of those, or I guess the things  
15 that were opened up in Alsea, Oregon.

16 Now I don't know exactly what the designs are  
17 that Dr. Griffith has in mind right at this time, but he  
18 is working also with Dr. Robert C. Duncan at the University  
19 of Miami School of Medicine, who is the primary biostatistician,  
20 and working together I think they are interested in looking  
at additional follow-on studies.

21 DR. HABER: Very good. Thank you, Dr. Stephenson.  
22 Dr. Kearney, would you care to tell us briefly where you  
23 are at in this problem and what you would like to be doing?

24 DR. KEARNEY: Yes. What might be of interest  
25 to the group is a meeting I attended earlier this month,  
June 3rd to the 7th, in Arlington, and it was a dispute

1 resolution conference that looked at the ability of science  
2 to interact in the decision-making process.

3 The model selected for that dispute resolution  
4 conference was 2, 4, 5-T and TCDD. I will not go into the  
5 philosophical aspects of the dispute resolution. Sixty-five  
6 scientists attended the meeting, with about 63 observers.  
7 There were several Italian scientists there who could  
8 comment on the Seveso situation. There were six workshops  
in the conference.

9 There was a workshop on carcinogenesis and  
10 mutagenicity headed by Dr. Jessie Steinfeld, former Surgeon  
11 General of the United States, now Dean of Medicine at the  
12 University of Virginia.

13 I have the conclusions of that workshop. There  
14 was a workshop on teratogenecity headed by Dr. Marshall  
15 Johnson at the Philadelphia School of Medicine and I have  
the conclusions of that workshop.

16 There was a workshop on human exposure headed by  
17 Dr. Austin of California. I have no affiliation.

18 There was a workshop on ecological effects. This  
19 was headed up by Dr. Ken Kamlett of the National Wildlife  
20 Federation, and I have the results of that workshop.

21 I have a report of the chemistry workshop which  
22 I was chairman of, and I do not have the results of the  
23 benefit workshop headed by Dr. John Staub.

24 I would feel most comfortable commenting on the  
25 conclusions of the chemistry workshop since they are  
pertinent to some of the discussions and some of the trials

1 discussed this morning.

2 We had eleven chemists in the workshop who are  
3 actively engaged in TCDD analysis in various forms. The  
4 first five questions of the workshop were philosophical  
5 and dealt with the role of the chemist and his participation  
with the decision maker.

6 The second five questions dealt with matters of  
7 chemistry and substance, and I think some of these might  
8 be of interest to you.

9 First of all, we dealt with what is known about  
10 the levels of detection of TCDD in the environment. It  
11 was generally agreed there is no level of TCDD in the parts  
12 per million or parts per billion range in any sample we  
13 have examined thus far, except as it relates to chemical  
disposal or spills.

14 It was further agreed that levels at 100 parts  
15 per trillion or above have not been detected in any  
16 environmental sample associated with 2, 4, 5-T. Here we  
17 are talking about fish, beef and mother's milk. Below  
18 these levels, that is, below 100 parts per trillion, you  
have to consider each of the studies individually.

19 First of all, dealing with mother's milk; based  
20 on three separate studies conducted up to January, 1979,  
21 no validated TCDD residues above 1 part per trillion had  
22 been detected based on the analysis of 44 mother's milk  
samples.

24 They concluded that there are no confirmed  
25 detected levels of TCDD in mother's milk.

1           In beef fat, out of 85 samples that have been  
2    surveyed thus far, one sample of beef fat confirmed at  
3    60 parts per trillion of TCDD, and two apparent, but  
4    unconfirmed samples at 20 parts per trillion. The  
5    remainder of the samples were below the level of detection,  
6    which is 10 parts per trillion.

7           We also looked at beef liver, bovine milk, fish  
8    and wildlife. These were available for your perusal and I  
9    will make copies of these conclusions available to the  
10   Veterans Administration if you would like those.

11           DR. HABER: Yes, we would indeed.

12           DR. KEARNEY: There are several other things which  
13    I think impinge on what is said here, and I will share  
14    those with you.

15           Concerning the manufacture of 2, 4, 5-T, the  
16    question was, is it not of interest to this  
17    group whether you can measure dioxin contents in commercially  
18    available samples of TCDD and make it commercially feasible,  
19    and the answer to the question is that yes, we can.

20           Are there problems in the disposal of the waste  
21    of this material? There would be problems, but we feel  
22    that we can overcome these, but I think germane to this  
23    discussion is, can TCDD be produced from 2, 4, 5-T? We  
24    concluded that a yield of 1 part per million of TCDD can  
25    be the result of combustion of 2, 4, 5-T, particularly when  
   it is mixed with organic matter.

26           Another question which I think is very pertinent  
27    to the biopsy study is, is 2, 4, 5-T the sole source of

1 the 2, 3, 7, 8 tetrachlorodibenzodioxin in the environment?  
2 This is important, and the answer is that it is not, that  
3 there are other sources such as combustion of certain  
4 chlorinated organic compounds, whether in commercial or  
industrial wastes.

5 That brings up another question which I think  
6 complicates the situation, but you must be aware of the  
7 fact that the chlorodioxins are a family of compounds of  
8 which there are 75 members. Tetrachlorodioxin, for example,  
9 is represented by 22 positional isomers. The 2, 3, 7, 8  
10 tetrachlorodioxin is believed to be the most toxic of that  
11 family.

12 It was assumed that the 2, 3, 7, 8 was the product  
13 of trichlorophenol. It appears there are other sources  
14 of the 2, 3, 7, 8 in the environment.

15 The question which the group also must consider  
16 is, can you detect the 2, 3, 7, 8 in the environment  
17 as opposed to the other positional isomers? The answer  
18 to that question is, yes, we can. It is very new  
19 technology. It requires very elaborate facilities, and  
20 it is a very highly sophisticated technology, and the  
21 cost of analysis is going to be about \$1,000 or more per  
sample.

22 The question is do we need more sensitive methods?  
23 What are the methods of measuring it in commercial samples  
24 and environmental samples?

25 The methodology which is available to us depends  
on the substrata at which we are looking. Now the current

1 levels of sensitivity having the appropriate specificity  
2 range from as low as .3 parts per trillion easily analyzable  
3 samples such as some of the fruits, to as high as 20 parts  
4 per trillion in certain animal and fat samples, and this  
5 is based upon certain appropriate chemical technology,  
6 what we call a signal to noise ratio of 2.5 to one.

7 The group also dealt with the environmental fate  
8 of TCDD, and I don't think that is of interest to this  
9 group. However, that information is available, so  
10 Mr. Chairman, these reports and these conclusions are  
11 available. They are unpublished at this time. There will  
12 be great speed to publish those, but the chairman of the  
13 conference has agreed to make these conclusions available  
14 to you.

15 Some of them are rather detailed in the field of  
16 medicine for which I have no expertise, but I think the  
17 group might benefit by having these.

18 DR. HABER: Dr. Kearney, thank you for a very  
19 illuminating presentation. First of all, let me express  
20 my gratitude for your making those available to us. The  
21 dispute resolution conference is precisely what we are all  
22 about, and I would like to have that made available to all  
23 of us, but I would also point out that I think that  
24 your dismissal of the fate of TCDD in the environment is  
25 something that does concern us, and I think we would want  
to look with great interest upon the finding in that  
regard because that is really one of the questions of  
people who went into Vietnam, where they came in contact

1 with the herbicides, and the fate of the TCDD contaminants  
2 would be of extreme importance to us, so we would be most  
3 grateful for any information about that.

4 Thank you again. We will appreciate getting  
5 those from you. We will make them available to the group.

6 Mr. Lemen, if you would be able to give us the  
7 same kind of summary, we would find it most helpful.

8 MR. LEMEN: NIOSH has had an active interest in dioxin  
9 since early this year when Secretary Califano received a letter from  
10 Mr. Cleland of the Veterans Administration requesting  
11 assistance in looking at industrial exposures to provide  
12 some light about what might happen as a result of environmental exposure.

13 As you all may be aware, industrial exposures  
14 oftentimes are very ideal for looking for epidemiological  
15 findings of a chronic nature simply due to the fact that  
16 occupational exposures tend to be oftentimes more intense  
17 and the ability to gather together a cohort or a group of  
18 people to study is oftentimes much easier in an occupational  
19 setting than what it is in the general environmental setting.

20 In attempting to do this, we have found that there are two  
21 groups studying the accident Mr. Cleland referred to in his letter  
22 to Secretary Califano that had occurred in 1949 in Nitro, West Virginia.

23 This was a Monsanto facility that had manufactured  
24 2, 4, 5-T. Dr. Raymond Suskind of Kettering Laboratories  
25 at the University of Cincinnati has been  
following the people from this accident  
since the early 1950's at the request of the company,  
Monsanto. At the same time, Dr. Selikoff of the Mount Sinai

1 School of Medicine was also looking at this same set of  
2 workers at the request of the local unions.

3 We have contacted both Dr. Selikoff and  
4 Dr. Suskind. Two and one-half weeks ago, Dr. Selikoff's  
5 group had just been on a field investigation utilizing some of our  
6 testing equipment to do a cross-sectional medical study of these  
7 workers. I have talked to him in the last several days,  
8 and he informs me that they will be ready to start putting  
9 together the analysis of the findings of this particular  
10 cross-sectional study shortly. They are currently waiting on some  
11 laboratory results and when they are received, we  
12 will be in touch with him to discuss the results of  
on the analysis.

13 Dr. Suskind has also been asked by the company  
14 to do a similar type of study, and he is planning to go into  
15 the field sometime in the near future and do essentially  
16 the same thing that Dr. Selikoff has done.

17 In addition, Dr. Suskind is planning to do  
18 mortality study looking at the mortality of the  
19 workers that were in this particular plant to determine  
20 if there is any excess of cancer or any other chronic long-  
term health effects as a result of their exposure to dioxin.

21 As you may know, carcinogenic effects generally  
22 take 20 to 30 years to manifest themselves after first  
23 exposure, and this population is just at reaching  
24 this period of time where one might be able to detect such  
chronic effects.

25 We at NIOSH are following the progress of these two  
studies at the Nitro,

1 West Virginia facility but we are not actively working in Nitro  
2 because we feel that there are two competent researchers in the  
3 situation now, and we will simply follow their progress  
4 and give them any assistance that we can.

5 We have decided to expand our investigation and are  
6 at the present time looking for other industrial accidents or  
7 exposures that have occurred over the years throughout  
the United States.

8 We have so far found several, the most recent  
9 being last week in Jacksonville, Arkansas. Dr. Selikoff and  
10 the State Health Officer, Dr. Young, contacted us  
11 about a particular plant which had manufactured 2, 4, 5-T  
12 for the past 20 years. The plant had stored the waste material  
13 in barrels which they had buried under the ground as well as  
some above the ground. The barrels now have begun to rust and the  
14 material inside (dioxin) has begun to leak and to begin contaminating the  
15 surrounding area.

16 There is a lot of concern not only for environmental  
17 exposure, but for protecting the workers that will have to clean  
18 this up and how do they clean it up?

19 We are in the process now of working with the  
20 state health department in trying to remedy this situation.

21 Basically, these describe the extent of the plans at the  
Institute at present.

22 We are still in our  
23 developmental stages of developing and proposing studies to  
determine what adverse effects result from exposure to dioxin, and  
24 we will keep the Committee informed as we take further steps.

25 DR. HABER: Thank you very much. That is very

1 helpful.

2 I would like to ask Mr. Robert H. Lenham, the  
3 special project officer of DAV, to give us his views and  
4 what the DAV's interest is and what they have been doing.

5 MR. LENHAM: Thank you, Dr. Haber. Some 58  
6 years ago, the DAV was chartered a disabled American  
7 veterans organization to set up to provide assistance to  
disabled veterans, and their families.

8 We are very concerned and have received  
9 correspondence in the mail from veterans throughout the  
10 country expressing their concerns over the possible  
11 exposure to the herbicide.

12 Immediately we set up a centralized system for  
13 handling these disability claims for dioxin poisoning  
14 and trying to collect evidence to substantiate these claims.

15 This is a problem because the medical records in  
16 most cases do not specifically reflect that a given veteran  
17 was exposed on such and such a date to any herbicidal spray  
18 that might have occurred in Vietnam, and we are aware of  
19 this, so when a claim comes in from a veteran, we refer  
20 this back out to our local national service officer who  
21 contacts a veteran, will assist him, sets up a special  
22 file, and then alerts us to any and all action taken on the  
23 local level by the VA Adjudication Service.

24 We have publicized in our monthly magazine the  
25 various effects that have been referred to us that could  
occur as a result of exposure to dioxin. We will naturally  
be interested in the reports that will be coming out of this

1 Committee and the other type of reports that will direct  
2 themselves to the problem that we are now confronted with.

3 This is a problem, alluded to earlier,  
4 that has gotten the attention of the nation, so in this  
5 respect, I am glad to be serving on this Committee to act  
6 as a veteran consumer and to be able to pass what information  
7 I might be able to have gained from our organization to  
8 the Committee members of maybe what the direct problems  
9 with which we are confronted by the veterans who are contacting  
10 us are, and hopefully maybe this will be of some assistance  
11 to the Committee members.

12 Thank you.

13 DR. HABER: Thank you very much. Dr. Lingeman,  
14 can you please let us know where you are at and where you  
15 are coming from?

16 DR. LINGEMAN: I would like to ask a question.  
17 Is this Committee interested only in the dioxins  
18 and the Agent Orange, or are we interested in other herbicides,  
19 which were used in Vietnam? How many others were used?

20 DR. HABER: I would say that our overwhelming  
21 interest is in solving the problem of exposure of American  
22 Armed Forces personnel in South Vietnam.

23 Now to the extent that we can help shed light on  
24 a world-wide problem, and to the extent that the Veterans  
25 Administration is increasingly aware of the fact of  
environmental hazards as a potential carcinogen or damaging  
agent, we, of course, are interested.

We have had intimations that

1 exposure of people during their Armed Forces career to  
2 asbestos might cause difficulties, and we are at the present  
3 time approached by veterans who have concerns about that,  
4 but I would say that is by far the less important objective.

5 Almost entirely we ought to concern ourselves  
6 with the potential damage done to American servicemen and  
7 women as a result of exposure to the herbicides that were  
used in Agent Orange in Vietnam.

8 DR. LINGEMAN: In other words, were significant amounts  
9 of other herbicides used in Vietnam during that period?

10 DR. HABER: There were other herbicides used I  
11 believe. There was an Agent Purple and an Agent White which  
12 were composed of cacodylic acid and picloram, but they were  
13 so trivial that it would be almost impossible to try to  
14 determine--their use was so trivial and infinitesimally  
15 less than the millions of gallons of Agent Orange that was  
16 sprayed that we can ignore them for the purposes of this  
discussion.

17 We are interested in shedding light on the whole  
18 subject of environmental toxicity, in particular for  
19 herbicides, but our main focus is on Agent Orange and what  
20 it did to the American servicemen.

21 DR. LINGEMAN: Thank you. This makes my  
22 description a little more simple.

23 The National Cancer Institute has for many years  
24 been interested in chemical carcinogenesis and devising  
25 methods to test for carcinogenicity. This is not a simple  
matter. There are problems with species specificity and

1 numbers of animals that must be used to provide a statistically  
2 significant result. The present Carcinogenesis Testing Program  
3 has the responsibility of determining which of 45,000 chemical com-  
4 pounds should be tested for carcinogenicity by the National Cancer  
5 Institute. The financial resources are very limited, and at the  
6 present time, it costs \$250,000 to test one chemical. The standard  
7 test in mice and rats involves a chronic study, usually oral feeding  
8 or installation by gastric tube of the chemical compound, sometimes  
9 other methods, depending upon the compound. At least two species  
10 of animals are required. At the present time, we use mice and rats,  
11 100 of each. We keep them alive, if possible, for their lifespan,  
12 which in the case of the mice and rats is between two and three  
13 years, and this has to be done under standardized conditions.

14 There have to be adequate controls. Before each assay is begun,  
15 it is necessary to determine for each chemical the maximum tolerated  
16 dose so that the dose will not kill the animals but will permit them  
17 to survive long enough to develop cancers. The Cancer Institute's  
18 primary mission is cancer. The emphasis has been there. However,  
19 when possible, we look for other toxic effects.

20 Recently, the National Cancer Institute's Carcinogenesis  
21 Testing Program has come under the National Toxicology Program, which  
22  
23  
24  
25

1 involves seven other government agencies, both regulatory and  
2 scientific, and is under the direction of Dr. David Rall of  
3 the National Institute of Environmental Health Sciences.  
4 From now on, our program will not be completely independent, and  
5 all chemicals nominated by us for testing will also be the  
concern of the National Toxicology Program.

6 I wish to tell you exactly where we stand with the  
7 dioxins and with 2, 4-D and 2, 4, 5-T since these are the  
8 materials of interest here.

9 The National Cancer Institute has a system whereby  
10 chemicals are nominated for test by means of a Chemical Selection  
11 Working Group composed of NCI staff and representatives of other  
12 government agencies. We hope to have a member of the Veterans  
13 Administration on this Committee soon. This is the nomination  
14 form which I will pass around. Anyone can nominate a chemical.  
15 We ask people to provide as much information as possible when they  
16 nominate a chemical. I think probably most of the chemicals of  
17 interest to this Committee have already been tested or are under  
18 test at the present time. When a chemical compound is nominated  
19 for test, the Chemical Selection Working Group meets with  
20 representatives from other government agencies who have an interest  
in this, including EPA, FDA and others. Members of these other  
agencies also serve on the Chemical Selection Working Group.

21 The Committee members vote on each chemical  
22 according to materials supplied by a contracting firm  
23 known as Stanford Research Institute, which provides information  
24 about each compound including amounts produced and imported,  
whether they have been tested previously, and other information.  
25

1 There has been a class study on pesticides in general and  
2 several pesticides other than 2, 4-D and 2, 4, 5-T have been  
3 tested or are under test.

4 We have to set priorities. Out of 45,000 chemicals,  
5 which are most likely to be carcinogenic, we take into account  
6 the chemical structure and similarity to known carcinogens, and  
7 the amount of human exposure. This is difficult to obtain.

8 I have a sample data sheet on benefin, another herbicide  
9 that has been nominated for test by the NCI. After the Working  
10 Group assigns a priority for those compounds selected for  
11 testing, each one is presented to a subgroup of the Clearinghouse  
12 on Environmental Carcinogens, composed of a group of  
13 advisers outside the NCI. They are the best experts we can  
14 find in the field. They meet approximately four times a year,  
15 and each of the nominated chemicals is submitted to this group  
16 for their opinions. These are open meetings. The subgroup  
17 reviews the evidence for each chemical, perhaps asking for more  
18 information, and then ranks them on the basis of 1-10, ten being  
19 the highest priority. We then have a list of chemicals ranked in  
20 order of priority to enter into the testing program.

21 This is a copy of the monthly report of the status of  
22 each of the chemicals which have been nominated for testing,  
23 those which are under test, and those for which tests are  
24 complete but the reports have not been published. We can  
25 make these reports available to the

1 members of this Committee.

2 The dioxins, TCDD and HCDD, are in final stages  
3 of the testing procedure. They are under pathology review.  
4 The protocols describing the results to be presented to the  
5 Clearinghouse subgroup on Risk Assessment/Data Evaluation are,  
6 being printed at the present time, and so I can't say  
7 anything about them yet because they have not been presented  
8 to the Clearinghouse. However, we expect that both of these  
9 compounds will be presented to the Clearinghouse in July  
10 or September, so that within the time frame of the work  
11 described for this Advisory Committee, these results will be  
12 available as technical reports. Here is an example of a  
13 technical report on another dioxin, DCDD, which was published  
14 this year. This and other reports are available either through  
15 the National Cancer Institute or through other government sources.

16 DR. HABER: That is excellent. Please continue.

17 DR. LINGEMAN: The International Agency for Cancer  
18 Research, under the auspices of the World Health Organization,  
19 meets periodically to discuss chemical compounds known or  
20 suspected of being carcinogenic. This is Volume 15, which was  
21 published in 1977 on the subject of some herbicides, which  
22 includes 2, 4-D, 2, 4, 5-T, and the dioxins, the compounds of  
23 concern to this group. This is a publication that Committee  
24 members should have access to, for it is an excellent summary  
25 of known health effects of these compounds in man and animals.

26 The other activities of the National Cancer  
27 Institute which have to do with this area involve the  
28 Epidemiology Branch, and I have not had an opportunity yet

1 to find out the precise details of all that might be going  
2 on there. As mentioned before, epidemiologic information  
3 documented with good pathology material is very difficult  
4 to obtain. By the time of our next meeting, I hope  
5 possibly to have some information about activities of the NCI  
6 epidemiologists in this area.

7 DR. HABER: Thank you very much. We are making  
8 very good progress. We are at the break time, but I think  
9 we have but one more presentation, and I would ask your  
10 forebearance for Dr. Murphy to make his presentation,  
11 and then we will break for lunch.

12 DR. MURPHY: I can probably be relatively brief  
13 since I have not been directly involved in research on this  
14 problem, and I do not really represent an agency. Although  
15 my name tag says consultant to the National Academy of  
16 Sciences, I really am not here representing the NAS.

17 I am merely speaking from the standpoint of a  
18 scientist who has been concerned with the toxicology of  
19 pesticides for some 20 years, with focus on primarily the  
20 insecticides, and have published several papers in this area.

21 For a number of years, I have from time to time  
22 served on certain expert committees of the World Health  
23 Organization dealing with pesticide residues in foods, and  
24 in the process of those deliberations, have gained some  
25 experience in going through the process of evaluating  
laboratory animal and epidemiological data with respect  
to ultimately coming to the conclusions concerning  
recommendations regarding the hazard or relative safety of

1 pesticide residues.

2 I am a member of the EPA Science Advisory  
3 Board's Environmental Health Advisory Committee, and as a  
4 function of that Committee membership, I chaired a study  
5 group on the contaminant pentachlorophenol, the contaminant  
6 in a particular pesticide which I think does have some use  
7 as a herbicide, but was not to my knowledge used in  
8 Vietnam, but the contaminants in that material of greatest  
concern are the halogenated or chlorinated dibenzofurans.

9 Dr. Moore was a member of that group, and we  
10 reviewed the knowledge base concerning the contaminant of  
11 pentachlorophenol. Tetrachlorodibenzodioxin does not appear  
12 to be a contaminant of pentachlorophenol, but the other  
13 dioxins that are, as Dr. Moore has indicated, produce very  
14 similar actions as that produced by TCDD, and there is  
15 a wide range of toxicities involved among the number of  
different isomers that are contaminants.

16 Some two years ago, I was a member of an ad hoc  
17 panel chosen by the National Academy of Sciences to meet  
18 with Italian health officials to evaluate and recommend  
19 possible collaborations in research on health effects  
20 associated with contamination of the environment around  
Seveso, which we have heard mentioned several times today.

21 The contamination resulted from an explosion of a  
22 reactor producing trichlorophenol near the town of Seveso.  
23 This Academy-sponsored panel met several months after  
24 the occurrence of the accident with the counterpart committee,  
25 and then subsequently this past March met again to review

1 the status of the studies that were largely being conducted by  
2 the Italian scientists in the area around Seceso,  
3 both laboratory and epidemiological studies.

4 In a very brief summary of the discussions of this  
meeting last March, from the studies conducted  
5 so far, there were three health effects that were  
6 observed that the epidemiologists' reported suggested  
7 association with this exposure to TCDD from the industrial  
8 accident.

9 These included chloracne clearly associated with  
10 the exposure, some suggestion of what was described  
11 earlier as hepatomegaly, and apparently some specific  
12 tests conducted showed some deficiency or slowing of nerve  
13 conduction.

14 The epidemiologists were developing plans for  
15 following a fairly large group of people over a long period  
16 of time in connection with the concerns for carcinogenic  
17 potential of TCDD, and one of the interesting observations  
18 was that the concentration of dioxins in the wild animals  
19 that roamed in the area did not appear to correlate very  
20 well with the incidence of chloracne that was reported,  
21 and I was very interested in Dr. Allen's comment concerning  
22 evidence of some effects reported in the peripheral areas  
23 of exposure, and I wonder what these relationships mean.

24 An interesting point that has come to my attention  
during these two committee activities, one in the EPA  
25 and this activity of the Academy, is what is the relationship  
between the dosage for effects in laboratory animals and

1 in humans, and this seems to be a rather illusive  
2 relationship.

3 In some respects, one would have almost  
4 anticipated that the Seveso incident would have been even  
5 more severe effects than apparently had been noted.

6 There was an attempt to evaluate the potential  
7 contribution to teratogenic actions in the human population,  
8 and so far, it appears that statistically nothing sorts out  
9 as a positive finding in that regard.

10 You asked for what kind of things we would like  
11 to see. Well, I would like to see the earlier NAS report  
12 after the Air Force report. I would like to see more about  
13 what is the nature of the designs of the studies that are  
14 now underway, and I wonder how much alternate designs  
15 have been considered, looking for clustering of possible  
16 effects and so forth.

17 What are the plans for long-term studies?  
18 You do have a group of human population that can be followed,  
19 but what are the plans for these, and to the extent possible,  
20 although as I said I don't represent NAS, I would hope  
21 to coordinate some of the information with the Committee  
22 on the National Academy of Sciences which has now been  
23 renamed to something like Committee on Response Strategies  
24 to Unusual Chemical Hazards, so they can respond to other  
25 things than Seveso.

26 DR. HABER: Thank you very much. That then  
27 concludes our morning. I must say that I am more optimistic  
28 at this moment than I have been for some months, that we

1 will find an answer, although that answer is not clear.

2 I would like to thank everybody for the morning's  
3 proceeding. Would the members of the Advisory Committee  
4 and the Steering Committee remain behind just a moment,  
please?

5 We will reconvene at 1:30 as per the agenda.

6 (Whereupon, at 12:15 p.m., the hearing was  
7 recessed, to reconvene at 1:30 p.m. the same day.)

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

## A F T E R N O O N   S E S S I O N

1:30 p.m.

DR. HABER: Let me reiterate if you will, please. For those of you on the floor who have questions, give them to Mrs. Meyer, dutifully sitting back there.

She will give them to me and I will attempt to read them. If they are relatively simple and are procedural, I will endeavor to answer them this afternoon.

Those that are more substantive, we will have some discussion from the Committee if the time allows, but I will tell you that we will get a position paper on it because I don't believe that the Committee yet is prepared definitively to answer. There may be differences of opinions which obviously is our job to resolve. So, while you might have some discussion about the question, that should be regarded as a tentative answer only in that the Committee will obviously want to deliberate further on some of the complicated questions, and we will adopt a position on it at some point, which will be made public either through the use of subcommittees or circulating documents through the committees all together.

I would like now to move along with our agenda. I think that because we did so well this morning in covering each of the participants on the Committee and their agency's specific orientation toward the problem,

1 think what I would like to do now is to engender some  
2 dialogue among the members of the Committee. Undoubtedly  
3 each of your comments excited some concerns, some questions,  
4 some suggestions on the part of the rest of the group.

5 I would like now to encourage us to go at that business  
6 to try to get some indications of what the substance of  
7 these deliberations are.

8 Dr. Allen, may I begin by posing a question to  
9 you? In your work with primates, you have reason to  
10 believe that there were birth defects, but were these  
11 confined to females who were pregnant at the time of  
12 exposure, or did you have any evidence suggesting that  
13 males could transmit damage that they sustained to the  
14 offspring of non-exposed females?

15 DR. ALLEN: Dr. Haber, I would like to answer  
16 this by first clarifying a point. We have observed no  
17 birth defects in the offspring of monkeys that have been  
18 born to mothers that have been exposed to the TCDD's.

19 There have been abortions, and most of these  
20 abortions occurred early in gestation. Those animals  
21 that were born to the mothers that were exposed prior to  
22 and during gestation, had normal infants, with the  
23 exception of being small. Otherwise, they were, generally  
24 speaking, small.

25 We have observed alterations in the menstrual

1       cycles, increase in cycle length and duration of the menstrual  
2       cycle, and alterations in progesterone levels in the females that  
3       have been exposed to the dioxins. We have not done thorough  
4       studies on the male Rhesus monkeys.

5       In our early report published in 1967, we did  
6       observe a marked decrease in spermatogenesis in monkeys  
7       that were exposed to high levels of dioxins, including  
8       the tetras, the hexas, the heptas, and the octachlorodibenzodioxins.  
9       Those of you that are older might remember the toxic fiasco  
10      that we had in the '50's, so we would expect, and we  
11      certainly would feel, that it does affect spermatogenesis.

12      We have observed no indications of a mutagenic  
13      nor teratogenic change in the animals so far.

14      DR. HABER: I am indebted to you for clarification,  
15      and I'm sorry I interrupted. I will tell you that Dr.  
16      Ton That Tung, the North Vietnamese physician who had had  
17      some experience with this several weeks ago came and briefed  
18      us, and when we put that question to him, although he  
19      had talked about birth defects in offspring of exposed  
20      females, he did not extend that to the males. He said  
21      he had no evidence of that, so it is a question of some  
22      concern to us.

23      DR. ALLEN: I also had the opportunity to visit  
24      with Dr. Tung while he was visiting the United States,  
25      and I think that I would like to say that in most instances,

1 the data that were presented by Dr. Tung were those of a  
2 practicing physician, and they were meager as to the  
3 information that they were able to relay to us.

4 DR. HABER: I can only agree to your observation,  
5 and I think Dr. Tung himself disclaimed any epidemiologic  
6 certainty from his findings and stated to us that they  
7 were suggestive only, that he was not an epidemiologist  
8 and portrayed himself as a practicing clinician in these  
9 observations, but of course, they were useful to us as  
10 observers.

11 I wonder, Mr. Lemen, if you could tell us a  
12 little bit more about the work of Dr. Suskind and Dr.  
13 Selikoff, if that is possible? I guess it was you who first  
14 suggested that?

15 MR. LEMEN: Fine. First of all, as far as  
16 results are concerned, I can't give you anything because  
17 Dr. Selikoff is just analyzing this, and I might suggest  
18 that you invite Dr. Selikoff or  
19 Dr. Marian Moses, who is the physician that was doing a  
20 majority of testing, to come to the Committee and present  
21 the results to you.

22 I can tell you the design of the study was that  
23 of a cross-sectional medical study, looking at workers  
24 who had been in the 1949 episode. Some had developed  
25 chloracne, and they were looking for any medical findings

1 in that group of workers.

2 At the present time, Dr. Selikoff has discussed  
3 the possibility of doing mortality analysis on the total  
4 work force. However, he has not started that.

5 Dr. Suskind has been following these people,  
6 according to my talks with him, since about the early '50's,  
7 and he has been looking primarily at dermatological  
8 conditions in the workers that were exposed to the 1949  
9 episode.

10 Dr. Suskind says that he is in the process of  
11 doing mortality studies. However, he does not have  
12 results on the mortality study to date. We will continue,  
13 as I said, to monitor both of these to try and get results  
14 as soon as they become available, but neither one of the  
15 two studies has any results that we can speak of today.

16 I think at the next meeting,

17 Dr. Selikoff's group would  
18 probably be able to talk to you about their findings.

19 DR. HABER: I think we might invite him to make  
20 a presentation to us. Does the group have any objection  
21 to that sort of thing if we were to invite people that  
22 you might suggest to make presentations to us?

23 DR. KEARNEY: I think it would be very helpful.

24 DR. MURPHY: I wonder, Mr. Lemen, in Dr. Suskind's  
25 studies, has there been any attempt to assess morbidity

1 from whatever cause other than dermatological? How  
2 about infectious diseases?

3 MR. LEMEN: Quite frankly, the information that  
4 we have received from Dr. Suskind has been a little bit,  
5 I don't want to use the word sketchy, but it is  
6 inconclusive, and I can't really answer that question.

7 He says that he is looking at the health effects  
8 in total among the workers, but in talking to him, it  
9 appears that it has been more of a dermatological evaluation.  
10 That is about the best I can do.

11 DR. MURPHY: Are Dr. Selikoff's studies designed  
12 to assess immunofunction?

13 MR. LEMEN: Yes, to my knowledge, they are. As  
14 you well know, though, in the cross-sectional type of  
15 study, it would be very difficult to detect any chronic  
16 long-term health effects such as cancer because those  
17 people tend to cluster in one population at the same time,  
18 so the type of studies without the aid of the mortality  
19 study would probably not answer the carcinogeneity  
20 question that you have posed, and also the question of  
21 teratogenic effect would have to be addressed in talking  
22 to family members and doing a fairly detailed questionnaire  
23 of the wives and offspring of those workers.

24 DR. HABER: I would like to comment, though, on  
25 this problem of chloracne, and invite any comments from the

1 Committee or questions about it.

2 The chloracne for us has a particular significance  
3 because it really constitutes a marker. If a serviceman  
4 comes to the Veterans Administration for treatment or for  
5 adjudication of a claim, if there are problems with  
6 substantiating the possible exposure, Dr. Levinson described  
7 this morning how we are trying to match the tapes on  
8 movements of various units in the Armed Forces with areas  
9 of known exposure to sprays, so that we can get some  
10 concurrence of data. One thing we do feel pretty  
11 confident about, is that if a veteran should have,  
12 any evidence of chloracne attendant upon his service in  
13 Vietnam, that probably would give us pretty clear evidence  
14 that he has indeed been exposed, so it would constitute  
15 a kind of a marker. We know that chloracne should  
16 occur within a matter of days or weeks or at least a few  
17 months after exposure; that it is not likely to occur  
18 years later.

19 Its first occurrence having taken place during  
20 the period in which he was in Vietnam or very shortly  
21 thereafter then gives us some feeling that there may be  
22 long-term other effects. Chloracne has been associated  
23 with systemic symptomatology and general pathology, so  
24 we feel a little bit more confident about that.

25 Is there any comment about this?

1                   MR. LEMEN: I have one question, and maybe the  
2                   Committee can answer it.

3                   Are there any levels below which you come in  
4                   contact with the Dioxin or 2, 4, 5-T that you do not get  
5                   the chloracne?

6                   DR. ALLEN:

7                   This was the question that I was looking at. From an  
8                   experimental standpoint, there can be reproductive  
9                   abnormalities in the females without showing obvious signs  
10                  of dermatological alterations.

11                  I have a question for Dr. Moore.

12                  DR. MOORE: Can I finish? I can add something  
13                  to his comment. There was a report in the British literature  
14                  several years ago in which there was accidental exposure  
15                  of several chemists trying to synthesize or work with  
16                  TCDD, and in those cases where they did come down with  
17                  clinical symptomatology consistent with dioxin exposure,  
18                  it occurred in the absence of chloracne.

19                  DR. HABER: What we are saying is that chloracne  
20                  is not a sine qua non for evidence of exposure. That  
21                  has been our suspicion, that people could have dioxin  
22                  poisoning, if that is possible, exposure, and not come  
23                  down with chloracne, but if they do come down with  
24                  chloracne, the burden of proof is upon him who says that  
25                  it was not due to exposure, and I think it has to be thought

1 of in that way. Where we find chloracne, we have got to  
2 really be very, very concerned. Where we don't find it,  
3 it still may be. Could you tell us a little bit  
4 more, Dr. Allen, about the dermatological abnormalities  
5 you saw in these monkeys and how long after exposure did  
6 they occurred? What would you say?

7 DR. ALLEN: One of the first indications that  
8 we had was in the let's say, for instance, the 500 parts  
9 per trillion. After they consumed 1 microgram per kilogram  
10 of body weight, we began to see the development of  
11 alopecia, loss of hair and dry, scaly skin, and if you  
12 look closely, you could see the accentuated  
13 hair follicles within a period of three months after we  
14 began to see indications.

15 In the 50 parts per trillion group, after they  
16 consumed in the neighborhood of 3 tenths of a microgram  
17 per kilogram of body weight, there were no obvious changes.  
18 However, we began to have indications of reproductive  
19 abnormalities that were obvious in these females.

20 DR. HABER: From ingested toxin?

21 DR. ALLEN: Ingested, not from dermatological  
22 or inhalation exposure.

23 DR. HABER: We have to keep in mind both  
24 possibilities. The troops or an exposed person may have  
25 wandered through areas infested with the

1 dioxin and become contaminated.

2 The other concern we have, of course, is that, and  
3 I look to Colonel Thiessen about this, there weren't  
4 too many dermatologists in the front lines so that the  
5 condition of chloracne might not have been precisely  
6 identified, but rather some other dermatological abnormality,  
7 trenchfoot or something like that. So we would be inclined  
8 to say that any dermatologic abnormality, unless it is  
9 pretty clear that it could not have been caused by dioxin,  
10 would have to be suspect.

11 Do you have any comment?

12 COL. THIESSEN: Individual cases maybe; I am  
13 not so sure whether an epidemic quote, unquote, of  
14 chloracne or acne or any dermatosis would have gone unnoticed.

15 DR. HABER: I didn't mean that. I just mentioned  
16 in individual cases that somebody might have ascribed  
17 that. It is conceivable at least that someone would say  
18 chloracne is a pretty tough diagnosis, and you have got  
19 to be a dermatologist to do it, and they were just corpsmen,  
20 so how would you have made that diagnosis at that time?

21 COL. THIESSEN: If the soldier had complained  
22 about a disfiguring acne, I'm sure that would enter into  
23 the record. I am certain of that.

24 DR. ALLEN: Dr. Haber, I have a question of  
25 Dr. Moore. One of the charges of the World Health

1 Organization, the group was to study the various industrial  
2 accidents.

3 Is there any feedback on this? What is  
4 happening with that charge? Are they pursuing this?

5 DR. MOORE: A number of those groups are being  
6 followed. The hope of the exercise was that the various  
7 groups that were studying their exposure here and their  
8 exposure there would come up with an agreed-upon questionnaire,  
9 a case history, so that there would be some consistency  
10 in what was looked for and the way it was they went about  
11 looking for it so that one could have the benefit subsequently  
12 of trying to amalgamate these various groups to get a  
13 bigger statistical cohort to try to look at.

14 At the time we met, which was a year ago January,  
15 nobody had been looking to the Nitro, West Virginia group  
16 subsequent to the actual accident which occurred in the  
17 early '50's, and the recent flurry of activity that we  
18 have found in the Nitro, West Virginia group is that it is  
19 a recent flurry of activity.

20 MR. LEMEN: Can you tell us some industrial  
21 sites that you are looking at?

22 DR. MOORE: They are in here. We are not looking  
23 at any sites. The sites that were identified by various  
24 people include some in Germany, some in this  
25 country, one in Holland, one in Germany. Obviously

1 the Seveso circumstance from a time standpoint was in its  
2 infancy.

3 DR. ALLEN: Are there epidemiological studies  
4 that are being financed by WHO?

5 DR. MOORE: No, not epidemiologic studies as  
6 such; basically morbidity, seeing what the cause of death  
7 is, et cetera, on some of these older groups, to see if  
8 anything will show up.

9 MR. LEMEN: We have been looking just to answer  
10 a little bit more, and we have not found, except for the  
11 Nitro situation, any epidemiological studies that are  
12 going on in the United States looking at dioxin exposures.

13 DR. HABER: At this juncture, it might be useful  
14 to have Dr. Schepers tell us something about this problem.  
15 He has looked into this, and has identified a number.  
16 Every time we consider it, it turns out there are more  
17 industrial exposures than anybody knew, and Dr. Schepers  
18 has what I believe is one of the more complete anthologies.

19 Would you please let us know about this, and  
20 maybe we ought to enter that into the record, the complete  
21 thing, and tell us about the exposures we know about.

22 DR. SCHEPERS: It is not terribly complete. I  
23 just happened to accidentally have it in one of my folders,  
24 but the first exposure of human beings to 2, 4, 5-TCL--  
25 it wasn't 2, 4, 5-T--was at the Nitro site, and that was in

1 1949. About 188 people were exposed there in the  
2 factory, and probably the children and wives, too, because  
3 there is recorded illness of those children and wives, so  
4 that the number of human beings could be quite sizable.

5 Now one of the problems with our group is to  
6 identify these individuals because after 30 years, they  
7 have been disbanded. I traced the actual Director of  
8 Personnel for the Monsanto factory to Mr. Baum through  
9 some friends of mine, and I am going to ask Mr. Baum if  
10 he has a record of all these people, and I think he has,  
11 so that we may be able to trace the human beings through him.

12 The next series of accidents occurred as four  
13 events in West Germany, from '49 to '74, and they  
14 can be found in the literature, and I would be glad to  
15 supply the Committee with details.

16 Then there was a group of two accidents in  
17 France from '56 to '66; 38 people were exposed to dioxin-  
18 containing materials there. They all developed chloracne,  
19 incidentally.

20 Then the next exposures were in the United States  
21 from the period '56 to '74, and these were the four separate  
22 events that most of you will know, that totaled to 81  
23 people. This is in Arizona, the group out there in Missouri,  
24 the horse farm, and so forth, and of course the employees  
25 of different chemical factories.

1                   Then in '62, there was a small accident in a  
2                   factory with five people exposed in Italy. In Holland,  
3                   there was a group exposed in '63 with 50 workers, and  
4                   they are being followed.; hyperlipema        and asthenia being  
5                   the main features so far identified.

6                   There have been two industrial accidents in  
7                   Russia between 1964 and '72. All the people recovered.  
8                   These two events were at intervals of eight years, all  
9                   symptomatic. The follow-up study is not known, but we  
10                  are trying to find out what happened to those people.

11                  Then in England in 1968 there was a single big  
12                  reactor leakage event, and most of the descriptions are  
13                  related to chloracne, but there are obviously  
14                  possibilities there.

15                  In 1970, there was a single accident in Japan. We  
16                  are trying to follow that.

17                  In Czechoslovakia in '72--there were very severe  
18                  industrial exposures, gross poisoning--six of the 55  
19                  workers actually died, showing the severity of the exposure.  
20                  Now that should be an extremely interesting group to  
21                  follow.

22                  Then in 1976 in Switzerland and Italy, that is,  
23                  of course, the Seveso incident, and that is the largest  
24                  single group. I understand there are about 70,000 children  
25                  under surveillance by the Italian government.

1                   I totaled up the    numbers of people in these  
2 incidents, and they come to almost 1,000 people, so that  
3 we have a fairly large group of human beings    that can  
4 be researched collectively.

5                   DR. HABER: I think one of the things that this  
6 Committee should be expected to do is to try to compile  
7 as complete a dossier as we can on the numbers of and kinds  
8 of such accidents therewith to stimulate the appropriate  
9 research by the appropriate agency, and hopefully to share  
10 in the results of such research.

11                  DR. MOORE: Dr. Haber, one of the best groups  
12 is that Czechoslovakian group that Dr. Schepers mentioned  
13 in that it has at least appeared in the literature. All  
14 of it has appeared in the literature. We have had those  
15 articles transmitted, and we will give you a copy of the  
16 translation.

17                  DR. HABER: I have asked our staff to do two  
18 things for us. One is to draw up a general chart of  
19 organization of the federal government and the private  
20 and academic sectors as well to see whether or not we can  
21 develop a kind of chart so that all of us can have a ready-  
22 made indication of who is doing what. This would be  
23 keyed with the number of studies, and I think each of us  
24 could use that so we could find out where the responsibility  
25 lies or who accepts responsibility for doing certain things.

1                   The other thing that I think might be very  
2 useful is, if we could begin to see, try to indicate some  
3 time lines so that we would have some indications as to  
4 when these studies would be complete, and we get some  
5 idea, at least in gross, about when we might expect some  
6 definitive answers.

7                   I know that some of it would take years to  
8 complete, but hopefully we would be able to get some clear  
9 indication that we can give to the public about the  
10 latest date the information would have been in. Maybe  
11 that can be improved upon.

12                  I wonder, Dr. Kearney, if you could tell us a  
13 little bit more about that conference on the dispute  
14 resolution because really that is what we are about, and  
15 it is the kind of a process in which I think this Committee  
16 would be very interested. If you could, give us any  
17 general guidelines as to how we use the scientific method  
18 to resolve a problem that is plaguing all of us.

19                  DR. KEARNEY: Well, I can provide you with the  
20 background paper. I think in a dispute of this nature, it is a  
21 question of how it could be resolved and what would be the outcome.

22  
23                  I suppose in some respects the first conference  
24 we had was largely discipline oriented, i.e., the field of  
25 medicine and chemistry dealing with specific subjects of

1 teratology and mutagenicity, carcinogenicity, human  
2 exposure.

3 The more philosophical question of how one  
4 deals with dispute resolution will probably be the next  
5 conference in which we would have local people, sociologists,  
6 political leaders, and others involved, but it does bring  
7 to mind something which I think is germane to these  
8 deliberations. It would be helpful to us  
9 the advisory panel to perhaps at some point clearly define  
10 what the Administration wants from us with regard to  
11 resolution of this dispute.

12 In other words, is teratology a legitimate  
13 subject for deliberation here? I don't know the answer  
14 to that question because were there females in  
15 the Vietnam area that are involved here in claims for compensation?  
16 Are we talking about males primarily, the number of males,  
17 and perhaps what you want us to focus on, because some  
18 of the issues are peripheral as far as we are concerned.

19 I don't know that we can answer that question  
20 today. As we get into this thing, these things will  
21 begin to surface.

22 DR. HABER: Well, I think that is part of the  
23 question I was asking Dr. Allen really because our concern  
24 is not exclusively directed towards males in Vietnam, as  
25 there were obviously women in the Armed Forces, and some

1 of them may have been pregnant at the time. Although  
2 such cases have not yet come to my attention, if the  
3 clear link is established that a pregnant female does  
4 produce a mutagen or a teratoma, and she can have  
5 claimed to have had exposure that would be something that  
6 would be useful for us to know.

7 On the other hand, a thousand, perhaps a hundred  
8 thousand times more likely just on the basis of the  
9 prevalence of people, would be the possibility that males  
10 thus exposed might transmit genetic damage to offspring  
11 by females not so exposed.

12 As I say, it seems to me that no clear evidence  
13 has been adduced to that effect, and I think that is  
14 something that, therefore, should concern us, but I would  
15 not turn my back on the other.

16 I think that we have an obligation first to  
17 look at our own problem, but I would say that we must not  
18 pass up the opportunity to contribute to the general knowledge  
19 if in so doing we don't obstruct our major objective.

20 I think it is appropriate  
21 for us to discuss teratology in pregnant exposed females,  
22 but it certainly should not loom very large in our  
23 discussions.

24 DR. SCHEPERS: May I comment on that?

25 DR. HABER: Please.

1 DR. SCHEPERS: You have answered many telephone  
2 calls, Dr. Castellot, and I perhaps more. This is  
3 probably the most distressing thing to the veteran. Many  
4 of the calls that I get is Doctor, I have just had a  
5 child, and the child is deformed. Is this due to Agent  
6 Orange?

7 They want an answer to that. Now Dr. Erickson  
8 told us today that he has perceived a decrease in neurological  
9 teratology an increase in heart and renal agenesis.

10 They mention club feet, cleft palate, the  
11 obvious things. Those are the things that distressed  
12 them.

13 We need to give them an answer on that. If  
14 there is an answer here, let's hope we find it, but it is  
15 a distressing thing, and I think this Committee should  
16 stay with that.

17 DR. HABER: Absolutely. I agree with Dr. Schepers,  
18 and I hope I didn't mislead anybody. I think that is a  
19 cogent subject for discussion, and one that we really  
20 should zero in on, and I think we have to focus on this  
21 to be able to reassure the veterans, if we can, which  
22 would be extremely useful.

23 On the other hand, if there is a reasonable  
24 doubt, I think we have to place that.

25 DR. MURPHY: I would like to ask a question of

1 Dr. Erickson and Dr. Allen in relation to this. With  
2 the kind of surveillance program that you have, Dr. Erickson,  
3 would the number of malformations that might be  
4 found in a group of, approximately 10,000 people, show up  
5 in this? Would there be a big enough blip in the ordinary  
6 incidence of things to show up?

7 I don't mean 10,000 malformations, but a whole  
8 population of 10,000 people.

9 DR. ERICKSON: It is possible. It is also  
10 possible that it would not.

11 DR. MURPHY: In general surveillance  
12 you don't focus on a select  
13 population, and I would worry about drawing conclusions  
14 from the kind of general trends you reported this  
15 morning.

16 The other question, Dr. Allen, you mentioned you  
17 didn't have any evidence of mutagenic or teratogenic  
18 actions. Is that correct?

19 DR. ALLEN: I think that, and I will refer this  
20 question after I have attempted to answer, to Dr. Lingeman  
21 here, if a compound generally speaking is carcinogenic,  
22 more than likely we will find it to be mutagenic. I  
23 think there is very little doubt that in animals, that  
24 TCDD is a carcinogenic agent. Thus, with the proper tools,  
25 I think we will likely find it to be mutagenic.

1                   Are you in agreement with that? I mean,  
2 generally speaking, we think of a carcinogen as also more  
3 than likely being a mutagen.

4                   DR. MURPHY: This is precisely what I was  
5 wondering about, and I think it has been reported mutagenic.

6                   DR. ALLEN: It is a very difficult compound  
7 with which to work, particularly in your system or  
8 whatever it might be .

9                   DR. MURPHY: Do you have tests on this?

10                  DR. MOORE: Carney in Canada did contaminant  
11 studies and reported this negative.

12                  DR. HABER: Repeat that.

13                  DR. MOORE: Carney in Canada has reported on  
14 a dominant lethal study which would be in effect for genetic  
15 damage in the male transmitted to the offspring which  
16 would be picked up by fetal absorption . His study was  
17 negative.

18                  DR. HABER: Could you give us that citation at  
19 some point?

20                  DR. MOORE: Yes.

21                  DR. HABER: Thank you very much.

22                  DR. KEARNEY: In that regard, the carcinogenesis  
23 work, we did address this. It did say that TCDD is a  
24 mutagen in two bacterial reverse mutation systems, and  
25 they cite the reference, but no correlates of mutagenicity.

1 have been found

2 Citing the reference, they also say TCDD is  
3 a carcinogen for rats, and cite four references, and mice,  
4 and cite two references.

5 DR. HABER: Is there any further discussion  
6 among the members of the Committee? One of the things I  
7 would like to ask the group to consider is,  
8 one of the problems we have is to translate  
9 the kind of data that Dr. Allen has presented  
10 into possible field exposures.

11 It is very useful to have his other detailed  
12 observations upon ingestion or exposure of a chronic  
13 nature to these toxic agents over a long period of time,  
14 and then to be able to make post-mortem pathologic  
15 diagnostic studies of exposed animals. That is clearly  
16 the first step, and it appears that in non-human primates  
17 and certain other species, that is pretty well along.

18 One of the things that I would like to ask the  
19 group to speculate and ruminate about, and maybe suggest how  
20 one could go about it, is, how does one begin to translate  
21 -that kind of quantitative data into how could we begin  
22 to get a grip on the likelihood of intensity of the exposure  
23 of human beings in the field?

24 In other words, how much exposure would somebody  
25 have to have to sprayed foliage and vegetation in order

1 to come up with dosages that might be comparable even in  
2 an order of magnitude to what Dr. Allen has been feeding  
3 his experimental animals?

4 What I am trying to get at is some feeling  
5 among the group as to how we could begin that process  
6 because I think that is an important element. Are we talking  
7 about the same order of magnitude or are we talking about--  
8 Dr. Moore?

9 DR. MOORE: I would like to make one request, if  
10 somebody doesn't have any information, and I will get on  
11 the bandwagon; in response to the question, it is my  
12 understanding that the use of Agent Orange in Vietnam, or  
13 herbicides in general, markedly decreased in the early  
14 '70's, and the bulk of herbicide exposure occurred in the  
15 late '60's

16 Keeping that fact in mind, it was only  
17 around 1970, '69, '70 that the concern about the level of  
18 dioxins in herbicides became an issue, and there was  
19 an overt attempt to reduce the level of dioxins which  
20 would suggest that the actual material that was sprayed  
21 would be higher than that which would be found on Johnson  
22 Island, which has been subsequently disposed of and was  
23 -analyzed. At least it was analyzed.

24 It is my understanding that samples of some of  
25 the pre-'69 or pre-'70 Agent Orange materials that were  
used do exist, and I would urge you to find if indeed

1 that is the case, and if it is the case, to see what the  
2 level of dioxins are that were in that material

3 DR. SCHEPERS: We have tried very hard to get  
4 a lead on where these samples could exist, and we can't  
5 trace them. If you know, let us know.

6 DR. KEARNEY: As you know, in '70 we did do some  
7 sample studies for manufacturers. We got back to '68 I  
8 guess, and then we asked for other samples, and we were  
9 unable to obtain them .

10 The problem also on Johnson Island, I think  
11 perhaps the Air Force has, is one could not identify lots  
12 to manufacturers in the rebarreling process. I think  
13 records became lost.

14 DR. ALLEN: Can you give us an idea? I know  
15 the Air Force reported as high as 47 parts per million  
16 I have heard unofficial reports that there were levels  
17 higher than this. Can you give us any insight as to what  
18 the levels of dioxin TCDD, was in the material that was  
19 being sprayed?

20 DR. KEARNEY: Dr. Allen, I wish I could. I am  
21 not sandbagging you. I simply don't know. I heard this  
22 figure of 50 also. We did not analyze the sample, but

23 apparently industry became aware of the problem and  
24 one manufacturer quickly tried to rectify it.

Others became aware of it later, and were unable to rectify it until the very end, toward the end of the situation.

I only wish we had those samples to analyze, but we can't get hold of them either. We haven't tried legal means, but we simply have not been able to get hold of them.

DR. HABER: I think this is a very important question, Dr. Moore. I think you are right on target. I think there are two parts of it. One is we need to-- Colonel Thiessen, maybe you can be of assistance to us--

Dr. Schepers has been unable to run down where such samples might exist, but if we could begin to isolate such samples, and then, allowing for decomposition and so on over this length of time, decide whether or not there was any TCDD at the time of the spraying. The second part of

that would be to translate spraying information into the possibility of exposure.

That seems to me to be a mathematical possibility, at least, but probably a very difficult epidemiologic task to perform.

COL. THIESSEN: As far as TCDD is concerned of course, all the information that is available is either in the Air Force report. I don't know if there are any of the samples still available that were used to determine the TCDD level.

On the other hand, though, I wouldn't be surprised

1 if a chemist, a manufacturing chemist could simply, looking  
2 at a production process, say something about a maximum  
3 level of TCDD possible. I thought you had a representative  
4 of Dow Chemical; he is not here any more, but I am  
sure that Dow could give that kind of information.  
5 Certainly I have never heard a level that high, but 50, 50  
6 PPM is, as I understand it, the level that was present in  
7 some samples; in most of the samples, the contamination was  
8 below 10.

9 DR. HABER: Can you tell us what steps we went  
10 through to try to get that information?

11 DR. SCHEPERS: Well, we went to the Army records;  
12 to the Air Force records. We went to the Dow Chemical  
13 Corporation, the Hercules Corporation, 18 different chemical  
14 corporations to see what records they have.

15 My genuine impression is that one, they did not  
16 know of this problem until around about the late '69, '68  
17 era, so that they genuinely did not know what the dioxin  
content was of the earlier samples.

18 My other impression is that the manufacturing  
19 process was fairly standardized so that the way the  
20 ingredients of Agent Orange were made in the '70's is  
21 probably the same way that this same material was made  
22 five years or six years earlier. There was no real change  
23 in the manufacturing method. Therefore, the probability  
24 is that the incidence of TCDD in 1970 was probably the same  
range as it might have been in 1963.

25 Now a lot of emphasis is often made on the

1 occurrence of large quantities, relatively large quantities  
2 compared to the experiments Dr. Allen has made, and when  
3 we talk of 50 parts per million, this is about 50 million  
4 times as much as you are using in your experiments, but  
5 often, not enough is said about the fact that quite a  
6 number of the samples that were tested had zero TCDD in  
7 them, and we don't know what the distribution was of the  
8 barrel with 50 in them, and the barrels with nothing in  
9 them, whether the analytical methods were sharp enough to  
10 be able to measure the presence of TCDD below one part per  
million.

11 We, of course don't know. I should rather suspect  
12 that the analytical methods were not available, but it  
13 almost becomes a moot issue when you, Dr. Allen, produce  
14 results at 10 parts per trillion, whether there was exposure  
15 to 40 parts per billion or 30 parts per million.

16 I don't understand the dimension. I see no  
17 relationship. It is just that there was a heck of a lot  
18 of TCDD in Agent Orange compared to your experiments.

19 What I would like to get from you is whether you  
20 have ever tried to calculate quantitatively how much dioxin  
21 is needed to produce an effect in an animal, what is the  
22 least quantity that will produce it, and then for us to  
23 relate that to the least quantity that we can identify  
24 in the herbicides used in Vietnam. That would be an  
interesting mathematical calculation.

25 DR. ALLEN: The only thing that I can say is  
that in my more recent studies, we have found that 50

1 parts per trillion in the diet when consumed over a period  
2 of approximately six months, and it is about 3 tenths  
3 of a microgram per kilogram of body weight, will produce  
4 reproductive abnormalities, and over a period of two years,  
5 a consumption of 1 microgram per kilogram of body weight  
will produce obvious signs, gross signs, of intoxication.

6 DR. SCHEPERS: Have you found a no effect level?

7 DR. ALLEN: Not in non-human primates, no. We  
8 are going down to lower levels at the present time, but we  
9 have not found a no effect level when the exposure has  
10 been extended over a period of time.

11 At six months when they have consumed 3 tenths  
12 of a microgram, we did not see any obvious signs of intoxication  
13 grossly with the exception of reproductive abnormalities.

14 If we waited two years, we did see signs.

15 DR. SCHEPERS: What about the experimental model  
16 to compare to the experience of a soldier who might have  
17 been in Vietnam say six months in an area, combat zone,  
18 where he might have been contaminated in one shape or  
19 another, either sprayed on his head or in his clothes or  
20 in his water or whatever, and then he leaves? Have you got  
21 anything in your experiments, animal experiments to match  
22 that? In other words, a short period of exposure in the  
23 life cycle of the animal and then wait and see; that is  
24 the one we are interested in.

25 DR. ALLEN: The only one, and certainly it is  
far removed from your particular example, is in the 500  
parts per trillion studies we had three that survived. We

1 have followed these animals now for approximately three  
2 years after they have been removed from the experimental  
3 diets. They have shown a dramatic improvement in their  
4 physical status. However, there are still abnormalities  
5 that we are encountering after three years of the exposure  
6 being discontinued.

7 DR. SCHEPERS: That would be the closest?

8 DR. ALLEN: That would be the closest that we  
9 have in our laboratory.

10 MR. LEMEN: You indicated this morning, though,  
11 that you did have tumors after two years on the ones that  
12 were sacrificed.

13 DR. ALLEN: We are talking about rats versus  
14 monkeys.

15 MR. LEMEN: Okay, but in the rat; you are talking  
16 about in the rats you saw the tumors?

17 DR. ALLEN: In rats, in the rats we saw the tumors.  
18 Monkeys are somewhat like the higher primates in that they  
19 do not develop tumors rapidly, so it requires a long period.

20 MR. LEMEN: I understand that, but in talking  
21 about the dose effect, if we are going to find anything,  
22 carcinogenic effects in Vietnam veterans, it is not going  
23 to occur for another 15, 20 years?

24 DR. ALLEN: That is more than likely correct,  
25 unless we have promotion of existing tumors.

26 MR. LEMEN: Right.

27 DR. HABER: I wonder, Dr. Allen, I understand you  
28 brought some slides with you. Would it be possible for us

1 to see those now?

2 DR. ALLEN: It's up to you.

3 DR. HABER: How long would that take?

4 DR. ALLEN: Five or ten minutes.

5 (A discussion was held off the record.)

6 DR. ALLEN: (Showing slides) We will go through  
7 these rapidly. If we could focus that just a little bit,  
8 this is just one of the non-human primates, the Rhesus  
9 monkeys that we employed, and I want you to pay particular  
attention to the hair coat.

10 If we could have the next slide--this is an animal  
11 of six months of exposure, and you will note the near  
12 complete loss of hair, particularly about the head, and  
13 the abdomen, shoulders, and if you look closely, the animal  
14 has practically no eyelashes, and the next slide will show  
15 you really what the animal looks like.

16 Here is another animal at six months. You will  
17 note the marked edema about the eyelids, the absence of  
18 eyelashes. You can't see the dry, scaly skin, but you can  
19 see the development probably on the side there, little  
20 acneform lesions, and I think the particularly obvious  
edema at the upper lips and generally all over the face.

21 This is just an example of some of the hematological  
22 changes we saw. At the top, it gives you the normal values  
23 of the monkeys and you will note in the white blood cell  
24 count we had a very decided decrease from about 9,000 down  
25 to in some of the animals about 2,000; of course, with the  
platelets, average of 327,000 down to 234450. You will note

1 the very decided decrease in platelets, and this is why  
2 we got what we feel is extensive hemorrhage.

3 The hemoglobin dropped from 13 down to 4, 6 and 8, as  
4 you see here, and of course associated with this is a  
5 decrease in hematocrits.

6 One of the more striking things that we saw was  
7 a marked thickening and proliferation of the finger-  
8 nails and toenails, and note the clubbing of the peripheral  
9 digit there. This we feel could have been associated with  
the very decided decrease in circulating red cells.

10 We also got dry gangrene. The peripheral digits  
11 would very frequently sluff off, associated with the dioxin  
12 intoxication.

13 Another thing we saw, rather striking, was the  
14 decided increase in the size of the gall bladder, maybe  
15 five or six times the average size, and here we have a  
16 probe introduced through the ampulla into the common duct,  
17 and you will note the tip of it, you can get an idea as to  
the size of this gall bladder and the ducts.

18 When we examined these, there was a marked  
19 thickening of the walls of the various ducts and the gall  
20 bladder associated with hypertrophy and hyperplasia of the  
epithelium.

21 This is just an example of the hemorrhage that we  
22 saw in the lungs of these experimental animals, and a  
23 rounding off of the heart, which was associated with the  
24 very decided anemia that these animals were experiencing.

25 This is just hemorrhage in the uterus. That was

1 very common in the animals that died.

2 The bone marrow, of course, there is the near  
3 complete absence of bone marrow, and the hemorrhage in the  
4 marrow.

5 The next slide shows hematopoiesis and a predominance  
6 of lymphoid appearing cells. Both the myeloid and erythroid  
7 elements were affected.

8 One of the more striking lesions was a marked  
9 thickening of the gastric mucosa, and to a lesser extent,  
10 the small intestine and large intestine. You note the  
11 hemorrhage on the surface of the stomach

12 The next slide will show us the reason for this  
13 thickening. About three fourths of the way up is the muscularis  
14 mucosa, and toward the top is the lumen of the stomach  
15 and the increase in glandular elements in the submucosa.

16 Could we have the lights on, please, and the  
17 slides off.

18 DR. HABER: Thank you very much, Dr. Allen. We  
19 are enlightened by your presentation.

20 I would like to call attention to the fact that  
21 Mr. Max Cleland, the Administrator of the Veterans Affairs,  
22 has taken time from his very busy schedule, and has flown  
23 in from Atlanta so that he could address this group.

24 ADMINISTRATOR CLELAND: I would like to thank  
25 you all for helping us in the Veterans Administration make  
some sense out of what has become possibly a very serious  
public health problem to Vietnam Veterans, and myself  
included.

1 I want you to know that I have a personal  
2 interest in the resolution of the questions surrounding  
3 Agent Orange. The Veterans Administration is quite  
4 concerned about the aftermath of exposure to Agent Orange,  
5 and we have picked you all to help us and lead us and guide  
6 us in the resolution of the questions surrounding Agent  
7 Orange.

8 One of the most difficult things I have had to do  
9 in the last few months is to try and answer questions about  
10 Agent Orange in a vacuum of ignorance, and in an area  
11 where even the scientists who are most knowledgeable about  
12 herbicides disagree.

13 That puts us in a very ambiguous and difficult  
14 position. We hope that this Committee will move with the  
15 greatest speed to resolution of these problems, which we  
16 face daily.

17 There are many interested citizens in this country  
18 who are concerned about the effects of herbicides on people  
19 and we are especially interested in the effects of herbicides  
20 on veterans, and whatever the data shows to be the case,  
21 so you all have a great challenge because we are greatly  
22 challenged as an agency that deals with veterans, and  
23 purports to deal especially with the health problems arising  
24 therefrom.

25 You are challenged to help us meet this quite  
serious question of Agent Orange, so I just want you to know  
that I am personally interested in your deliberations. I  
look forward to reading the minutes that you all have

1 accumulated today. There are others who will follow every  
2 word, and each point raised with much interest.

3 You have a great responsibility. I know you will  
4 tackle your job very well.

5 I thank Paul Haber for leading this Committee  
6 in its deliberations. I know that there will be a great  
7 deal of give and take and a great flow of information, and  
ideas and sharing of opinions and views.

8 I urge you to do that because we look upon you  
9 as the mechanism by which we can air all the complaints  
10 or ideas or fears, and especially the scientific data  
11 surrounding the questions of Agent Orange and herbicides  
12 used in Vietnam, so I just speak as the head of the  
13 Veterans Administration, and also as a Vietnam veteran,  
14 urging you to tackle your job seriously, and especially as  
15 Administrator thanking you for your willingness to take  
16 time from your busy schedules to help us with this most  
serious question.

17 Paul, thank you very much for the opportunity to  
18 visit. I know you have some other items on your agenda  
19 and I won't interfere. I will now resume my duties, but I  
20 did want to visit with you personally and tell you where I  
21 was coming from and how much we needed you to guide us in  
the future.

22 Thank you very much.

23 DR. HABER: Thank you, Mr. Administrator. I am  
24 very encouraged by this morning's discussion. It looks  
25 like we are beginning to make real progress.

1 ADMINISTRATOR CLELAND: Thank you very much.

2 DR. HABER: Thank you, sir. Dr. Allen, would  
3 you care to resume your presentation?

4 DR. ALLEN: (Showing slides) This is just a  
5 typical example of the marked thickening that occurs, and  
6 the gastritis that develops in animals exposed to the  
7 dioxins. Very frequently there are ulcerations that are  
8 also associated with this hypoplastic gastritis, and in  
9 my instances, we feel that these severe changes in the gastro-  
10 intestinal tract are associated with the demise of the  
experimental animals.

11 Dr. Moore and his associates have done a  
12 considerable amount of work with the effects of the dioxins  
13 on the immune capabilities of the animals, and certainly  
14 in our experimental animals we got a marked decrease in the  
15 lymph nodes throughout the body. This is just a typical  
16 example of hypocellularity that occurred in the lymph node,  
17 and with the decrease in cellular population, of course,  
18 there was necessarily a decrease in the immunologic response  
of the experimental animals.

19 This is hair follicles. You note the swelling  
20 of the eyes that occurred in the experimental animals. This  
21 is what they looked like microscopically, and the hair  
22 shafts are filled with keratinized material.

23 This also occurs to a lesser extent in hair  
24 follicles over the surface of the body.  
25 One of the more striking things that we saw was the marked  
changes that occurred in the epithelium throughout the body;

1 changes in cell types suggestive of, quote, possibly  
2 transformation of one cell type to another.

3 This happens to be pancreas, and generally  
4 speaking, there are very few, if any, mucous secreting  
5 cells in the epithelium.

6 Here we have a marked increase in the cells.  
7 They would normally be in the epithelium. They would be  
8 stratified in the epithelium.

9 Here we have a change in cell type. The same  
10 thing occurred in the salivary glands, and also in the bile  
11 ducts, indicating a change from one cell type to another  
12 as a result of exposure more than likely to the dioxins in  
one way or another.

13 We also saw marked changes in the transitional  
14 epithelium of the urinary bladder, not only changes in cell  
15 types, but also a piling up of the epithelium.

16 I just wanted to show you the reproductive  
17 abnormalities that occurred. It would appear that this  
18 is one of the more extensive. If you look only on the left  
19 side here, there is the 50 parts per trillion study animals,  
you then note the 500 ppt; compare the two. Total impregnated,  
3 of 8 on 500 ppt. and we got 100 percent in our control  
20 animals on both experiments.

21 Total impregnated with 50 ppt, six of eight  
22 abortions, with four of eight in the 50 ppt and two of  
23 eight were normal births on  
24 50 parts per trillion, two of eight, and one of eight on 500 ppt.

25 Also one of the more critical things that we are

1 concerned about in our study is the effect upon fetal  
2 development, and as quickly as we are able to have sufficient  
3 numbers of infants survive, we will also be doing learning and  
4 behavioral studies in an attempt to see if there are any  
5 deficiencies.

6 We have found with other halogenated hydrocarbons  
7 alterations in the learning capability, and the animals  
8 show behavioral deficits, so we will be pursuing these  
9 particular questions.

10 That's it.

11 DR. HABER: Thank you very much, Dr. Allen.  
12 Those slides speak eloquently of your work. We are  
13 indebted to you.

14 DR. MOORE: Dr. Haber, could I just make a  
15 comment about dose which is where we were going earlier?

16 I think one of the things that I feel very strongly  
17 about is that despite all of the work that is available  
18 experimentally or anything else with respect to the  
19 benzodioxins, we do have some understanding as to the  
20 kinetics of TCDD in the rat. We have a bit of data of TCDD  
21 in the primates, but we don't have good comparative  
22 pharmacology, and until we get that type of data, we are  
23 going to be hard pressed or whistling in the wind in trying  
24 to extrapolate from primate or rat or guinea pig into dose  
25 the same as man because we don't have good dose response  
ratios.

26 DR. KFARNEY: That brings up another point. I  
27 notice in our schedule that the last five minutes will be

1 devoted to future meetings. I am wondering if it is in  
2 order in light of the fact that you have represented  
3 on this panel various sources of expertise and what  
4 they can get from their agencies. However, due to a number  
5 of things which are evolving, there are people who now  
6 have summary information on such things as human exposure,  
7 and I don't think the group is aware of it.

8 I only became recently aware of this myself. I  
9 am wondering if at some time we could spend more than five  
10 minutes talking about the future meetings, as to what sort  
11 of things we need to hear, for us to make some sort of an  
intelligent decision?

12 In other words, I think this thing of human  
13 exposure is very important. I think the Environmental  
14 Protection Agency has taken the point of view that if the  
15 risk is high, that is suspect as a carcinogen, and if the  
16 exposure is low, then the hazard is low. If the exposure  
17 is high and the risk is high, then the hazard is very high,  
18 and these kinds of deliberations go into making some sort  
of an option on the pesticide.

19 We may have to take that same thinking process  
20 to deal with this situation. What I suppose worries me  
21 a little bit I guess I don't understand what the levels  
22 of exposure in Vietnam were, and maybe we won't get to that,  
23 but I would like maybe the Air Force to give us their  
24 thoughts on this, if someone can do this.

25 I am aware of some exposure research underway  
right now on 2, 4, 5-T, which I think might be usable to us.

1 I am aware of someone who is beginning to summarize the  
2 teratology data. I think it might be helpful if we could  
3 bring these people before the group and gain what we can  
4 from them. I think this is rather important as to where  
5 we go from here.

6 DR. HABER: Let me explain the item that is  
7 labeled 3:25-3:30, future meetings. That was to decide  
8 only the date of the next meeting. It was not to attempt  
9 to address any substantive issues, but only to take five  
10 minutes to agree upon a date, but I think that the composition  
11 of the Committee is mandated by the charge we have in "The  
12 Federal Register."

13 That does not, however, prevent, and I would  
14 certainly suggest that we should bring before the Committee  
15 experts of whatever stripe or disciplinary background or  
16 persuasion that we can get in order to enlighten us. TW

17 In other words, this group is not yet complete. TW  
18 We have had a recent resignation for reasons that I won't DD  
19 go into here, and a replacement will be sought for that I  
20 individual, but except for that, I think the group is pretty TW  
21 well set. It was chosen very carefully, and I think that  
22 I would only echo Mr. Cleland's confidence in the group.

23 Again, if we need outside expertise, that is not  
24 of the group, from whatever source, we can obtain it and  
25 should, and I would say that people who can provide us with  
it ought to be available.

I think this Committee will continue to meet  
periodically as we see fit, but again, we should be able to

1 make available to us all kinds of expertise, and I would  
2 be completely subject to the wishes of the Committee. I  
3 think that if any of you wishes to suggest a presentation  
4 by somebody, we can certainly arrange for that as soon as  
5 appropriate.

6 I would like at this point to distribute--there  
7 are a number of copies for the group here, and there may  
8 be enough for members of the audience as well--and these  
9 are some questions which we will refer to the Committee to  
be answered.

10 We will prepare position papers on all of these  
11 questions unless we feel a question is encompassed in another,  
12 along with questions from the audience.

13 If any of you have any written questions, would  
14 you please submit them to Mrs. Myer so that we can--because  
15 what I would like to be able to do is to address--let me  
16 go over this list of questions briefly, and I will endeavor  
17 to secure answers to these in the form of position papers.  
18 I will quickly read these questions, and if anybody has  
19 any comment or further question, please feel free to mention  
them.

20 These are questions framed by our Steering Committee  
21 through the Advisory Committee. Remember the Steering  
22 Committee, with Dr. Levinson as the chairman, are the action  
23 group, and we are the advisory group here. If they need  
24 information or advice about particular aspects of the Agent  
25 Orange problem, each work group is  
to find the answers itself or to get the answers from others.

1 I will quickly read these. One, do the available  
2 data on exposure of Vietnam veterans to herbicides permit  
3 the performance of scientifically valid epidemiological  
4 studies on the long-term health effects of herbicides  
in this group?

5 I think that clearly is a substantive question  
6 for which we will endeavor to get an answer. As I say,  
7 we will have position papers in answer to each of these  
8 questions which would be made available to the public and  
9 will form part of the record.

10 Two, what are the best human population groups in  
11 which to study the long-term effects of herbicides on health,  
12 and how may these studies best be conducted?

13 That relates to the question you just mentioned.

14 Three, of what diagnostic value are the following  
15 procedures in assessing possible herbicide toxicity: levels  
16 of dioxin in fat pad biopsies; study of immune factors;  
17 study of chromosomal patterns; and study of liver microsomial  
enzymes?

18 What additional diagnostic procedures should be  
19 considered?

20 The first of those will be answered by Dr. Lee's  
21 study, and he will be communicating that to us as soon as  
22 those studies are completed, and it may be that Dr. Lee  
23 and Dr. Hobson will have to advise us where  
24 those studies will lead and whether indeed they would  
generate other studies of a similar nature.

25 We have, as I have indicated, a number of suggested

items for research that Dr. Hobson and we will be responding to presently.

Question 4, is it possible for herbicides to have long-term adverse effects on the male reproductive system?

That question certainly surfaced. We recognize it, and we will continue to pursue that.

Five, what topics should be included in the educational curricula being developed to upgrade knowledge of potential herbicide toxicity among VA staff members?

One of the things we have tried to do before is to make the staff of our field hospitals responsive to the needs of veterans who come in complaining of dioxin poisoning or toxic effects of dioxin.

This is a continuing process. We get out information to our field as quickly as possible. Dr. Lee's study will have some effect on this. Physicians had to be brought on board with respect to the possible toxic effects, and he has gotten cooperation from a number of hospitals in doing these biopsies, so this itself contributes to the general knowledge on the part of our professionals throughout the hospitals.

Six, what sorts of animal studies would make the most important contributions to understanding the potentially toxic effects of herbicides in humans?

Clearly it is an important question.

Seven, what additional data should be included in the VA's herbicide registry over that being currently produced?

1                   Dr. Castellot, can you tell us about the herbicide  
2                   registry and where it is now? Is that a fair question?

3                   DR. CASTELLOT: I can't give you any specific  
4                   data in terms of how many names have been entered into the  
5                   registry, but at the present time, on a quarterly basis,  
6                   each of the field facilities, and there are 172, are required  
7                   to submit data on the individuals who have presented  
8                   themselves or were sought out in their particular geographic  
9                   area with regard to herbicide exposure, and as you heard  
10                   this morning, the history and physicals and other laboratory  
11                   data which are accumulated at that time are submitted to  
12                   the Central Office for review. That review is an ongoing  
13                   process.

14                   Dr. Levinson has the specifics in terms of the  
15                   numbers involved, but it is an ongoing process and will  
16                   be accumulated and will eventually I'm sure be subject to  
17                   rather specific analysis in terms of determining any trends  
18                   that may be developed, but that is an ongoing process  
19                   here in the Central Office and the multi-disciplinary  
20                   board which is reviewing all of these, so it is not done  
21                   by any single individual.

22                   Many of the people on the Steering Committee  
23                   are involved with that as well.

24                   DR. HABER: Eight. What are the known facts on  
25                   the persistence of dioxin and the herbicides used during  
26                   the Vietnam War in water, soil and the atmosphere?

27                   Can these media serve as a source of human  
28                   exposure to dioxin and herbicides?

1           We have touched on that, and clearly we need more  
2 data on the chemical formulations and how they persist.

3           Nine, what medical tests should be utilized  
4 to help establish a diagnosis of chronic herbicide-induced  
5 toxicity among Vietnam veterans?

6           One of the most vexing problems we have when  
7 veterans come to us is when a veteran says I don't know.  
8 I think I have been exposed, and I don't know whether I am  
9 sick or not. Can you please study me and tell me whether  
10 indeed I am harboring long-term ill effects of dioxins  
11 unbeknownst to myself, and what test would one do?

12           Well, faced with a situation like that, all we  
13 can do is the general physical, complete blood count,  
14 X-rays, general EKG, electroencephalogram, and so on.

15           There is no laboratory test at this point which  
16 would say yes, you have been exposed or no, you haven't.  
17 Liver profile, sperm count, all of those things are  
18 done when people come in with symptoms referable to that  
19 particular organ system, but unless the biopsy or the fact  
20 proves out, and if it does, we may have albeit a difficult  
21 and not trivial biopsy procedure that will be of help, if  
22 our current pilot studies prove out.

23           Ten, can criteria be established for determining  
24 the level of exposure of military personnel to dioxin during  
25 the Vietnam War based on spraying tapes and unit histories?

26           We will undertake to try to answer that.

27           Finally, will it be possible to develop standards  
28 and criteria which define the precise relationship between

1 herbicides and dioxin with chronic adverse effects in  
2 humans?

3 Can these criteria also specify the reasonable  
4 limits between the time of exposure to herbicides and the  
5 development of disease?

6 These questions have been submitted by our  
7 Steering Committee, and as I indicated to you, we will get  
8 answers for them and position papers on each of them.

9 I have here several questions submitted by the  
10 floor, and I will undertake to read these. If the answer  
11 is quickly forthcoming, we will attempt to give it to you.  
12 If not, we will treat these questions in the same way  
13 that we would those submitted from our Steering Committee  
14 and provide position papers in answer to them.

15 One, what is the U. N. doing concerning Agent  
16 Orange which may have an effect on U. N. troops that served  
17 with us in Vietnam?

18 Does anybody around the table have any answer  
19 to that?

20 Okay. We will undertake to get an answer and  
21 give it to you. Who submitted this? Does anybody want  
22 to be identified with that? Do you have any further  
23 amplification?

24 MR. GERKEY: No.

25 DR. HABER: We will try to get an answer.

26 MR. DE YOUNG: There has been some rumors around  
27 that we have heard that Australia and the Republic of Korea  
28 have taken a claim to World Court; something having to do

1 with troops being poisoned. It is total rumor, to my  
2 knowledge. I think it is totally false.

3 DR. HABER: We will undertake to find out that  
4 at the same time.

5 Next question, when is it likely that significant  
6 results from the Ranch Hand study will begin to become  
7 available?

8 Colonel Thiessen, can you give us any answers  
9 on that?

10 COL. THIESSEN: The results of the retrospective  
11 study, which is basically the questionnaire type study of  
12 all 1200 people, should be available by the end of 1980.

13 The cross-sectional study is the physical study  
14 on selected individuals and should go on at more or less  
15 the same time. It should also result in data at the end  
16 of 1980.

17 Of course, the prospective study will take years,  
18 but there will be interim results at the end of '80, '81  
19 and so on and so forth, until 1985 when the study is con-  
20 sidered to be finished.

21 DR. HABER: That is something I would like very  
22 much for our Committee to be able to do. As I indicated  
23 to you, I have done that, so we would like to try to get  
24 some answers as to when the definitive study will be  
25 completed.

Obviously everybody needs to know that from a  
policy standpoint. It is extremely important.

DR. ALLEN: You are going to get us the

1 experimental protocol on this?

2 DR. HABER: Yes, sir. I have made that agreement  
3 with them, and General Dettinger was very forthcoming and  
4 said he would.

5 MR. LEMEN: I have one question. You said that  
6 the prospective study was going to be cut off in 1985?

7 COL. THIESSEN: That is as the plans are now.  
8 Our protocol will be before the Committee for approval.

9 MR. LEMEN: My comment is that if you  
10 are looking for carcinogenic effects, you probably  
11 would miss them if you cut them off the study in 1985.

12 DR. HABER: We are very mindful of that in the  
13 VA, and we intend to follow identified people.

14 MR. LEMEN: Have you got a group already  
15 identified.

16 DR. HABER: I think that when we get the protocol  
17 we can make that comment. I am sure they will have to  
18 match men with capability and money and so on, but on  
19 the other hand, I think that while we want quick answers,  
20 I think it is incumbent upon those of us who are following  
21 these people to be prepared to follow them for a long  
22 period of time.

23 Dr. Hobson has talked to me about that several  
24 times, so we are well aware of that: 4.2 million veterans  
25 reportedly may have been exposed to Agent Orange. I  
think that is probably not true.

I don't think 2.4 million people  
were in Vietnam. However, the question is, is gross

1 information on subsequent health of many of these  
2 individuals available, and might it be useful?

3 There is no question that it would be useful. I  
4 would say the information--who asked that question?

5 MR. STONE: I was just wondering with the protocol  
6 that has been made, of perhaps trying to contact very large  
7 numbers of the individuals who may have been exposed.

8 The 4.2 million figure I believe comes from VA  
9 testimony last October.

10 DR. HABER: I hope not.

11 MR. STONE: Before the Subcommittee on Health.

12 DR. HABER: I gave that testimony, and if it is  
13 in there, it is a misprint.

14 MR. STONE: Perhaps they had the figures reversed.

15 DR. HABER: I think so.

16 MR. STONE: The proposal has been made that  
17 perhaps a general notification process of veterans who may  
18 have been exposed would be justified, and that useful  
19 information might be forthcoming.

20 DR. HABER: That is certainly something that is  
21 very much in our minds. That would be an extremely tedious  
22 expensive and difficult action to take, but on the other  
23 hand, if the facts warrant that, and if that is the advice  
24 of our Advisory Committee, if that is what they think,  
25 then we would undertake to do that.

I think that is something that is very good.

Dr. Schepers gave me a note.

DR. SCHEPERS: The question is whether we have  
health records on Vietnam War veterans. They are mostly

Acme Reporting Company

1 young people, and they are still employed mostly, and  
2 so they don't come to the veterans hospitals, but we are  
3 already currently seeing about 150,000 of these Vietnam  
4 War veterans in our hospitals annually, so we are developing  
5 an enormous amount of medical information of a general  
6 kind about them, and this information is available to  
7 the Committee through Ms. Kilduff.

8 DR. HABER: The VA expressed extreme scepticism  
9 about the possibility that dioxin would be traceable in human  
10 tissue of even heavily exposed veterans. What will be  
11 the significance of a finding from the present tests of no  
12 detectable dioxin cases?

13 Well, it is difficult for me to anticipate  
14 the answer, but I think, and I  
15 will ask Dr. Hobson to comment on this, what our present  
16 study is designed to do is to tell us whether or not a fat  
17 biopsy would be useful in distinguishing between people  
18 who have been exposed to dioxin in Vietnam, and controlled  
19 subjects.

20 If that turns out to be the case, then we have  
21 a potentially, maybe not definitive, but useful  
22 way of determining whether others who claim they were  
23 similarly exposed do indeed store  
24 dioxin in their fat tissues.

25 It does not specifically say no, you could not  
26 have been exposed, and we don't pretend it is. Larry,  
27 do you have anything you want to say?

28 DR. HOBSON: No, except that we would not, under

1 any circumstances be going beyond the data if with the  
2 detection methods we had available to us, we could not  
3 find any in the fat. If it is there, we would give the  
4 amount that we were able to detect.

5 DR. LEE: Quite evidently if you find dioxin  
6 in the fat, it means there has been exposure, but it does  
7 not say when or where. Neither does it say that there  
8 will be disease as a result of it, either currently or  
9 in the future.

10 If you do not find dioxin, it does not say you  
11 were not exposed, and it does not say that you won't have  
12 future difficulty from the exposure if dioxin was there.

13 As Dr. Haber pointed out, the only thing this  
14 will do, if there is dioxin present in those exposed and  
15 not in controls, is to tell you that these are individuals  
16 who can and should be followed, and that they do have known  
17 exposure proven, simply by the fact that the dioxin is in  
18 their tissue.

19 I might also say that those people who are exposed  
20 agriculturally or in the manufacture, probably have the  
21 same problem. It may be that we should put in a third  
22 group that would be a control group from neither industry  
23 nor from the agricultural people to see if they have the  
24 same sort of thing.

25 At the moment, all we know is that we have 16  
26 people who had had a biopsy, and if there is dioxin in any  
27 of them, we will find out if it is in the controls or the  
28 others, and it does not indicate that they are or will be

1 sick, or that they won't be.

2 DR. HABER: Thank you. We have here a number  
3 of questions addressed to specific members of the panel.

4 Incidentally, the gentleman who said the 4.2  
5 million quotes correctly. That is what the testimony said.  
6 That was an error, and I want to retract that. It was 2.4  
7 million. It was a typographical error.

8 MR. DE YOUNG: There is good reason from where  
9 we sit in Chicago to say that 4.2 million is probably an  
10 accurate figure, the reason being that many stateside bases  
11 under the Freedom of Information Act have admitted to using  
12 2, 4, 5-T during that same period of time, and so it  
13 is very reasonable to assume that anyone who was in uniform  
14 at that time came into contact with it, possibly in lower  
15 dosage at stateside, but into contact with it.

16 DR. HABER: That opens up a whole new range of  
17 possibilities.

18 MR. DE YOUNG: We have reports from men in Panama  
19 who said the jungle was defoliated. In Louisiana, it was  
20 made to resemble Vietnam by defoliation and so forth.

21 DR. HABER: That is a very interesting piece of  
22 information that we will have to deal with, so we will  
23 take that under consideration, too.

24 A number of questions have been addressed to  
25 various members of the panel. To Dr. Erickson--what is  
the usual percentage of wasted pregnancies in the population?

DR. ERICKSON: It depends how hard you look.  
The best studies that I know of come from the Hawaiian Island

1 of Kauai where something on the order of between 25 and  
2 30 percent of pregnancies were wasted. A typical figure I  
3 think is something on the order of about 15 percent. It  
4 depends how early into pregnancy one is able to ascertain  
5 the fact of pregnancy.

6 MR. LARSON: Please define wasted.

7 DR. ERICKSON: I presume that meant lost at  
term, live birth.

8 MR. DE YOUNG: I can define it. The toxicologist  
9 in Chicago used the term to mean any pregnancy that was  
10 not delivered of a healthy child, a pregnancy that was in  
11 some way abnormal, possibly a still birth, possibly  
12 spontaneous abortion, or a birth gross deformity.

13 The figure he gave was 10 to 15 percent, and I  
14 wanted to see what CDC's figures were on that, if you  
had any.

15 DR. ERICKSON: CDC doesn't have any figures of  
16 their own, but this Hawaiian study was of a population on  
17 a small Hawaiian Island where all the women of reproductive  
18 age were registered and followed on a monthly basis so  
19 that very early pregnancy losses could be determined and  
20 studies where you will find the figure of 10 to 15 percent,  
21 usually the ascertainment of pregnancy is later into  
22 pregnancy, and there is a quick falloff from a fairly high  
23 in early pregnancy to a lower level later in pregnancy.

24 MR. DE YOUNG: Thank you.

25 DR. HABER: The next question is addressed to  
Dr. Kearney, and it is, what are the other ways, quote, unquote,

1 of production of 2, 3, 7, 8, TCDD, other than TCP?

2 DR. KEARNEY: What are the other sources of the  
3 2, 3, 7, 8 other than in the production of the 2, 4, 5?

4 DR. HABER: Right.

5 DR. KEARNEY: Well, there appeared, and I don't  
6 have the dates on this exactly, in '75, '76, reports from  
7 Europe that industrial incineration was giving rise to  
8 dioxin materials, and these are reports from Rappe, and  
9 Dr. Otto Hüssinger from Amsterdam, and Dr. Boozer at  
Boshart in Switzerland.

10 It appeared that any situation where you had  
11 chlorine and industrial wastes that were incinerated at  
12 high temperatures, could be a  
source of dioxins.

13 The Dow study went further than this. They  
14 repeated the European studies. They looked at mufflers.  
15 They looked at wood burning fires. They looked at  
16 industrial incinerators, and they looked at municipal  
17 incinerators, and there were dioxins associated with each  
18 of these, so this raises the question -- are there other  
19 sources of dioxins other than the production of trichlorophenol  
20 and it raises a question as to the biopsy study--do you  
21 have proper controls so that you would see Vietnamese veterans  
22 not in Vietnam who were not exposed, although this  
23 question of the Vietnam veterans not in Vietnam being  
exposed raises another complication.

24 DR. MURPHY: Dr. Kearney covered it, but the  
25 question asks 2, 4, 5-T at least as you traced it, and I

1 think he pointed out trichlorophenol, which I think is  
2 important to recognize, 2, 4, 5-T is not the only product  
3 through which trichlorophenol, in the production of  
4 trichlorophenol that you get the TCDD, and wherever you are  
5 producing that--many processes.

6 DR. HABER: My understanding was that it was  
7 a degradation product as well as a deformulation product.  
8 Is that true?

9 DR. KEARNEY: Now you raise a very interesting  
10 question. For example, I understood the question to say  
phenol, but maybe it said 2, 4, 5-T.

11 For example, in Italy what was being produced  
12 there was trichlorophenol for the production of  
13 hexachlorophene and most of the explosions in Westphalia  
14 were trichlorophenol-producing plants rather than 2, 4, 5-T  
15 producing operations, so that is a question.

16 You can get pyrolysis of certain phenols and  
17 2, 4, 5-T, and you can produce TCDD. It is also possible  
18 that is a source, so that there appear to be a number of  
sources, and this does further confound the issue.

19 That's all I am prepared to say.

20 DR. HABER: Thank you. Dr. Lingeman, you have  
21 been asked to answer two questions. You asked about other  
22 herbicides used in Vietnam, and if the Committee was to  
23 address the story with Agent Orange; do you have any  
24 information on their health effects which leads you to ask,  
25 and are you recommending this study?

DR. LINGEMAN: Other herbicides are known to

1 be carcinogenic, including several  
2 arsenal compounds; some of the inorganic compounds are known  
3 and accepted as human carcinogens.

4 One of the others in Vietnam was picloram. It  
5 has been tested by the National Cancer Institute and there  
6 was a possible increase in hepatic nodules which are  
7 considered by some to be pre-cancerous conditions in rats,  
8 so yes, the answer to the question is other herbicides are  
9 known to be carcinogenic, and possibly toxic in various  
ways.

10 DR. HABER: I think the question would be are  
11 you recommending such a study?

12 DR. LINGEMAN: If other herbicides were used  
13 concommitantly with Agent Orange, I believe that they  
14 definitely would be relevant.

15 DR. HABER: Our information is the amount they  
16 used was almost trivial. Is that not true?

17 MR. LEMEN: Just to add on to what you have said  
18 one of the things that concerns me is the massive use of  
19 the related compounds, particularly the pesticides used in  
20 Vietnam that have thus far not been addressed.

21 I would like to agree with you to  
22 say that I think the pesticide issue is one that may well be  
23 just as big as the herbicide issue, and we should certainly  
24 look into it at the same time.

25 DR. HABER: I think that is important, and  
we should obviously address the official charter of this  
Committee, the VA Advisory Committee on Health-Related

1 Effects of Herbicides, but I am sure that narrow  
2 construction was because of our main concern about Agent  
3 Orange, but it would not stand in the way of our getting  
4 other information made available.

5 One final question from the group. This one was  
6 signed by Mr. Donald A. Larson. To what extent is information  
7 potentially available on the effects of Agent Orange on the  
indigenous Vietnam population?

8 I would like to answer that and that is to say  
9 that there is information available in the original National  
10 Academy of Sciences report, and then we have the report of  
11 Dr. Tung, and other people, which we have to look at  
12 more carefully and continue to see whether or not we can  
13 get updated information.

14 I think Dr. Tung is anxious to cooperate with us.  
15 Wasn't that your impression, John? You may have been here  
16 when he briefed us and expressed the desire that he could  
17 continue to work with us, and I think we will certainly  
18 try to make available from him any information which is  
of value.

19 I think Dr. Allen has already characterized it  
20 as lacking the quantitative sophistication that we are  
21 accustomed to, at least in this country, and one has to  
22 understand he was in a war-time condition and maybe some  
of the niceties couldn't be observed.

23 MR. LARSON: I meant general. That was an isolated  
24 instance. I meant general.

25 DR. HABER: As I said, we will endeavor to review

1 the minutes. If we feel the questions have been  
2 definitively answered, we won't deal with it any further.

3 If it was a more substantive question which could  
4 not have been answered precisely and must therefore only  
5 represent a tentative view, we will develop a position  
6 paper on this.

7 There are two people who I would like to specifically  
8 call on if they are present. Mr. Frank McCarthy, is he  
9 present, or is Mr. Michael Gerkey present?

10 MR. GERKEY: Did you have a question you wanted  
11 to ask me?

12 DR. HABER: I was informed by the Administrator  
13 that you might wish to make a statement, and if you do,  
14 this is the time and the place.

15 MR. GERKEY: Okay. Then I guess I will have to  
16 do it.

17 What I am basically concerned about is the effect  
18 of Agent Orange on the world, as there were people from  
19 different parts of the world who served with us in Vietnam  
20 who most likely, if we were affected, would have been affected.

21 They were part of the United Nations. I feel  
22 that if any research is to be done to help us, there should  
23 be research done to help them also, and they should be made  
24 aware of the effects of Agent Orange on the populations in  
25 their countries. There should be some sort of a world  
organization set up to work with scientists and work  
with people in the Veterans Administration and work with  
people at the local level, at the state level, at the

1 government level, along with the military level, and  
2 I believe one should look into this matter and pursue it.

3 DR. HABER: That's good. We are indebted to you.  
4 I think that is an excellent suggestion. There have been  
5 a couple of indications around the floor that the people  
6 in the U. N. may have been involved. I think it is only  
7 fair that we make some representation through the  
8 Administrator's office to the World Health Organization, or  
9 some other international body, and offer to share with them  
10 the possibility of our getting data on that, so we will  
do that.

11 In the future, we will have opportunities for  
12 those of you in the general public who wish to make prepared  
13 statements to the group, and we will, in our "Federal  
14 Register" notification, indicate that if anybody does wish  
15 to make such a prepared statement, if he submits it to us  
16 before, he would then be asked to read it before the  
general group, and we will make provision for that.

17 This being our first meeting, that has not been  
18 deemed possible, but I would suggest that if others  
19 in the audience wish to make brief statements not  
20 exceeding five minutes in length, we would be anxious to  
21 accommodate you, so if anyone wishes to make such a  
22 statement, will you please come to the microphone and  
23 identify yourself and please confine yourself to no  
more than five minutes.

24 MR. DE YOUNG: Frank McCarthy is not here today.  
I saw Frank in Kansas City last week and Frank said

1 essentially that he didn't feel it was worthwhile coming  
2 because he thought the purpose of this Committee was to  
3 whitewash the subject.

4 I no longer think that. I no longer think that.  
5 I came here specifically to watchdog this Committee from  
6 my point of view.

7 Let me get into my prepared statement, and maybe  
8 it will make some sense.

9 I am the Veterans Services Coordinator at Columbia  
10 College in Chicago. It is under the VISA program funded  
by HEW.

11 Eighteen months ago, an extremely agitated woman  
12 appeared in my office in Columbia College in Chicago. Her  
13 name was Maude DeVictor, and she was at that time a VA  
14 Benefits Counselor at the Chicago Regional Office.

15 She told me of 27 cases of cancer among Vietnam  
16 veterans she had seen there in the Chicago Region. They  
17 all had one thing in common besides cancer. All served  
18 in areas of Vietnam defoliated by the now almost mythical  
Agent Orange.

19 She went on to show me the research she had compiled-  
20 articles from scientific journals showing evidence of  
21 the herbicide 2, 4, 5-T's ability to cause skin problems,  
22 cancer, miscarriages, mutations, and birth defects; letters  
23 and notes of phone conversations with scientists and researchers  
24 who provided further statements documenting the contamination  
25 of herbicide with dioxin, that most toxic of all man-made  
chemicals.

1           She further told me that she had written the VA  
2   Central Office   repeatedly about this and received no response.  
3   The claims for service connection for these men had not  
4   been granted.

5           We decided that the veterans of the Vietnam  
6   War had the right to know if Agent Orange had caused  
7   these problems 5, 10 and 15 years after their exposure, so  
8   we asked Mr. Bill Kurtis with WBBM-TV, CBS in Chicago to  
9   have his investigative team research Agent Orange and its  
dioxin contaminant.

10           For six weeks they traveled the country pulling  
11   in all the loose ends, and trying to weave together the  
12   pattern of dioxin poisoning that had emerged in so very many  
13   widely scattered episodes--dead horses in Missouri, and the  
14   sick owners who had sprayed dioxin-contaminated oil on  
15   their horse barn; dead Rhesus monkeys in an experiment done  
16   by Dr. Allen in Wisconsin; deformed goats and ducks and  
17   sick people in Globe, Arizona; sick residents of the national  
18   forests where Agent Orange like herbicides were still in  
use; and of course, veterans of Vietnam from Chicago.

19           In all those episodes, some common symptoms  
20   emerged--skin problems, hair loss, joint problems, headaches,  
21   nausea, fatigue, psychological changes, blood disorders,  
cancer, and birth defects.

22           The documentary that grew out of this, called  
23   "Agent Orange: Vietnam's Deadly Fog," was aired on March 23,  
24   1978 in Chicago. WBBM referred calls to my office, and the  
25   ensuing weeks found me with an epidemic of calls from

1 Vietnam vets saying they, too, showed these problems--  
2 hundreds of phone calls from all over the midwest from  
3 vets talking about skin rashes persistent since Vietnam;  
4 severe headaches; joint pains and swelling, often mistakenly  
5 diagnosed as arthritis, and resistant to treatment;  
6 nausea and continued fevers, some for seven years; extreme  
7 debilitating fatigue; an endless progression of sick days,  
8 days they had not been able to work; and an unending series  
9 of colds, flu and other common ailments; mysterious stomach  
10 disorders, intestinal disorders, urinary disorders, kidney  
11 disorders, liver disorders, auto-immune responses; allergies  
12 and blood disorders; and nervous system problems, typically  
13 numbness of the hands, arms, feet and legs; a collection  
14 of psychological changes--tempers, violent behavior,  
15 depression, anxiety, brooding, memory loss, confusion, an  
16 inability to cope with the pressures of life, a loss of  
17 resiliency, and cancers and tumors in men 25 to 35 years old.

18 Some doctors have described those as almost  
19 unheard of in men that age.

20 They also reported difficulty in conceiving children  
21 after their return from Vietnam. Many of them reported a  
22 loss of interest in sex or physical impotence as well.

23 Some reported multiple miscarriages by their  
24 wives, often followed by the birth of a child with severe  
25 physical deformities, typically of the fingers and feet,  
heart murmurs, and cleft palate, as well as hyperactivity  
and learning disabilities of various sorts.

26 What was the VA response? "No firm evidence

exists to incriminate these herbicides." Men who were legitimately worried about their health and their children's health were brutally turned away with the statement that their problems couldn't be from Agent Orange, that it was all in their heads, and were sent to the shrink.

The news media in various cities picked up that story. The Chicago pattern was repeated first in St. Louis, then New York, Los Angeles, San Francisco, Denver and Detroit. Each time the media carried the reported symptoms, calls from Vietnam vets poured in.

Hundreds of claims were filed and denied. "No firm evidence exists." Months later, a tissue biopsy was instituted by the VA as a first step in determining whether these vets had been poisoned by dioxin. In Chicago, the tests were so badly handled that three vets in Chicago are suing the VA for malpractice.

The first VA advisory committee on toxic herbicides was established by the VA Central Office last year. It was so flagrantly in violation of the Federal Advisory Committee Act that it was abolished and this Committee formed, an action that took a year, and which we applaud.

VA Central Office promised to issue instructions to all medical facilities on how to test Agent Orange victims. As late as three weeks ago, VA doctors were still asking vets what is Agent Orange.

A document came to us which authorized the destruction of certain tumor and cancer registry records, and immediately here comes a letter from the VA asking for

1 at the same time spokesmen from the Central Office were  
2 assuring me that all medical records would be preserved and  
3 sent to the National Cancer Institute.

4 Mr. Cleland denied any knowledge of the destruction  
5 of those records. Veterans all over the country have  
6 called in to tell us of the run-around, ignorance, the futility,  
7 the red tape, the insolence, and the outright malpractice  
8 of the VA health care system. The VA seems to have lost  
9 all credibility with this country's Vietnam veterans. It  
10 has broken faith with us by not telling us the whole truth  
11 at first. We got PR statements carefully worded to avoid  
any conclusions or responsibility.

12 Is it any wonder vets have not been beating down  
13 the VA's doors in haste to get medical care? Until the  
14 VA gives vets their legally mandated benefit of reasonable  
15 doubt and aggressively researches the Agent Orange, vets  
16 will stay away. Until the VA gives vets their rightful  
17 first-class medical care, courteously, sympathetically, and  
18 with dignity befitting their status as the warriors of our  
society, vets will stay away.

19 The VA must take the lead in Agent Orange research.  
20 In the past, VA doctors have won international awards for  
21 contributions to medicine. I hope that is not over. The  
22 VA must act immediately not in its own interest or in the  
government's interest, but in the interest of the vet.

23 Information must be gathered, and the start has  
24 been made, not only from the manufacturers of the  
25 chemicals, but from scientists and doctors and researchers

1 without the vested interest of the petrochemical industry.  
2 The fox cannot watch the chickens.

3 Information must be sought from vets themselves,  
4 from service and fraternal veterans organizations, from  
5 environmental groups and individual citizens. The word  
6 must be put out to all Vietnam veterans--you may have  
7 been poisoned. Come in and get checked, but before we do  
8 that, we must have programs in place to do the testing,  
9 extremely subtle testing, checking more than just blood,  
10 chest and urine, and then we must provide treatment, and none  
of us knows where to begin on that.

11 Then there are children. Current claims by  
12 veterans that Agent Orange has deformed their children get  
13 administratively disallowed in that cold exactness of  
language so favored here in Washington.

14 These men want to know if their own government  
15 has crippled their children, and if they can safely have  
16 more children, and they need answers soon.

17 Because vets need these answers now, and because  
18 the VA has lost credibility, many of us of whom the  
19 Agent Orange questions were first asked a year and a half  
20 ago, veterans groups and citizens groups from all over  
21 the country have joined together to look for these answers,  
22 answers that can be believed.

23 We have organized an Agent Orange Task Force to  
24 seek out those answers and help those vets. This group is  
25 composed of representatives from ten veterans organizations  
nationwide, including the National Association of Concerned

1 Veterans, the Vietnam Veterans of America, the Vietnam  
2 Veterans for Self-Reliance, Vetline/Hotline, Agent Orange  
3 Victims International, Concerned American Veterans Against  
4 Toxins, and others.

5 We extend an invitation to other veterans groups  
6 to join us in this effort. We are gathering information  
7 on Agent Orange from veterans and researchers all over  
8 the country, and respond with the best answers we can as  
9 we go. These answers will not protect the chemical industry.  
10 They won't protect the government or protect the military  
11 or the VA. They will protect the vet.

12 Secretary Califano of the Department of Health,  
13 Education and Welfare has assigned the Assistant Surgeon  
14 General, Dr. James Dickson, to analyze our caseload data,  
15 looking for the patterns of illness emerging. Dr. Dickson  
16 will also listen to scientists, researchers, and doctors  
17 who have information on dioxin poisoning.

18 Secretary Califano has played his department's  
19 aggressive action to find answers to the questions of Agent  
20 Orange. We take him at his word, and hope this second  
21 herbicide committee will be as aggressive in the interests  
22 of Vietnam veterans.

23 The eyes of the nation are on this Committee.  
24 Twice as much of these herbicides were sprayed here in the  
25 U. S. as was sprayed on Vietnam. Whether they know it or  
not, the outcome of this Committee is important to every  
citizen of this country.

26 On top of the spectre of Three Mile Island, we

1 now have the spectre of Agent Orange, and I may add of  
2 Agent White and Purple and Blue and Green and Pink.

3 I am here today with John First of Southern  
4 Illinois University. I mentioned in my prepared statement  
5 that St. Louis was the next city after Chicago to report  
6 a large case. In about five weeks, John had 607 phone  
7 calls for more information about Agent Orange.

8 I would like him to take five minutes, if you  
9 wouldn't mind, and let him go through the data that he has  
collected on that.

10 DR. HABER: All right.

11 MR. FIRST: I would like you to know that we do  
12 not consider this scientific information. What we wanted to  
13 do more than anything was find out what the people were  
complaining about.

14 We asked them to tell us what they had experienced  
15 since Vietnam. In an effort to avoid pre-disposing their  
16 answers, we chose not to ask specific questions until they  
17 had nothing further to add to their spontaneous remarks.

18 We have two tallies here. I would prefer to  
call them accountings. Of the 607 reports that we got,  
19 89 reported nothing but their name and address so that  
20 they might receive further information. We received no  
21 information from them.

22 Of that 607, 301 reported numbness and tingling.  
23 That is 49 percent; 305 reported various rashes. A  
24 significant number of those rashes were reported to have  
25 acne-like eruptions. They come and go with time. They

1 are often reported to increase in severity with heat.

2 This tally includes a list of birth defects that  
3 are reported. I am not a doctor. I do not know the  
4 significance of these. I make them available to you in  
5 the hope that you will know whether or not they are significant  
in the general population figures.

6 We totaled 55 veterans with full intake, at which  
7 time we now have 89 percent reporting a rash. This is not  
8 a scientific sampling. They called on their own response  
9 to published symptoms which they recognize, for which they had  
10 failed to receive adequate treatment.

11 I do have copies of this available for the Board.

12 DR. HABER: We would appreciate that very much.  
13 Incidentally, let me now say that we would appreciate any  
14 representations from any interested parties--scientific,  
15 lay, of whatever description, and would undertake to make  
16 this information available to the concerned members of the  
17 Committee.

18 Additionally, anybody who wishes to make a  
19 presentation to us at times other than the meeting, can do  
20 so by writing or calling my office and arranging for such  
21 an opportunity. We would grant him a hearing, in addition  
22 to which we will have opportunities at future meetings for  
23 public statements of the kind we just had, to be read into  
24 the record, and the questions to be exercised.

25 I see by the clock that we are right on schedule,  
and I wish to thank both the Committee and the audience  
for helping us meet that precise time limitation.

1           I would like now to take a few moments to simply  
2       set the date of the next meeting, which ought to give us  
3       time to prepare our papers and to circulate documents  
4       among us.

5           Notwithstanding the fact that we are in the midst  
6       of the summer and people's schedules are disrupted, I  
7       would like to set this meeting for early in August, and my  
8       first cut will be August 9th.

9           Can you all determine if that is not possible  
10      for you? Dr. Murphy? When would be?

11       DR. MURPHY: Late in August.

12       DR. HABER: Supposing we make it early September,  
13       September 7th. Is that a possibility? Can everybody make  
14       it?

15       DR. KEARNEY: I will be in Europe.

16       DR. HABER: I think this is going to be difficult  
17       to do this way. I therefore think that it would be  
18       best to circulate several dates to all of you by  
19       some written communication, and then we will ask you to  
20       circle the most propitious date, and when we get the  
21       greatest number of attendees, we will convene.

22       Is that satisfactory to the members of the  
23       Committee?

24       MR. LEMEN: Yes.

25       DR. HABER: Dr. Schepers reminds me if you cannot  
26       attend, your alternate who has been named could attend,  
27       but we would like to keep the group as much as possible to  
28       this representation. We will give you ample opportunity to

1 indicate any problems.

2 MR. LEMEN: I have a question. You said that  
3 we would develop position papers. Are you going to be  
4 writing to us then to ask us to comment on these?

5 DR. HABER: Yes. We will handle these position  
6 papers in one of two ways. We will endeavor to make a  
7 preliminary statement which we will circulate to the group  
8 for corrections, or if we feel incapable of doing that, we  
9 will ask a small group of you, or one or two of you to help  
10 us frame the original paper, and then circulate it. You  
11 will not be tasked until I specifically contact you.

12 Is there any further business of the members of  
13 the Committee? If not, please accept my heartfelt thanks  
14 for what is a challenging and difficult task. I think it  
15 is well begun. I think I have gotten several new ideas.  
16 I am indebted to all of you for the dispatch and scientific  
17 way in which you have approached this very, very difficult  
18 subject, and I have no question but that we will produce  
19 the answers sooner because of the existence of this  
20 Committee than would otherwise have been the case.

21 Thank you all very much, and we stand adjourned.

22 (Whereupon, at 3:30 p.m., the hearing was  
23 adjourned, to reconvene at an undetermined date.)

1

2

3 REPORTER'S CERTIFICATE

4

5 DOCKET NUMBER:

6

7 CASE TITLE: ADVISORY COMMITTEE ON HEALTH-RELATED EFFECTS  
8 OF HERBICIDES

9 HEARING DATE: June 11, 1979

10 LOCATION Washington, D.C.


11 I hereby certify that the proceedings and evidence herein  
12 are contained fully and accurately in the notes taken by me  
13 at the hearing in the above case before the  
14 VETERANS ADMINISTRATION  
15 and that this is a true and correct transcript of the same.

16 Date: June 18, 1979

17   
18 Official Reporter

19 Acme Reporting Company  
1411 K Street N.W.  
Washington, D.C. 20005

20 I HEREBY CERTIFY THAT THE PROCEEDINGS AND EVIDENCE HEREIN ARE CONTAINED  
21 FULLY AND ACCURATELY, AS CORRECTED.

22   
23 PAUL A. L. HABER, M. D.  
24 Chairman  
25 Advisory Committee on Health-  
Related Effects of Herbicides

26 August 7, 1979

595646